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ABSTRACT: 
Crystallization occurs under a variety of conditions including inside the human 
body. Many of these processes are undesirable diseases, which require pharmaceuticals 
or surgical procedures as treatment. Hematin, a toxic compound, crystallizes in malaria 
parasites to prevent eradication from the body while cholesterol crystallizes in the 
gallbladder and arteries creating blockages of vital fluids. In malaria, the parasite mutates 
to become resistant to current antimalarials while atherosclerosis exhibits no signs until 
heart attack, stroke or death. For these diseases, new pharmaceuticals are imperative as 
preventative medicine. However, knowledge of these phase changes is limited as no one 
has performed systematic studies to fundamentally understand crystallization or 
inhibition in physiologically relevant environments. With this knowledge, a platform for 
the design of potential drug compounds could be implemented. 
For malaria, gallstones, and atherosclerosis, both lipid and aqueous media are 
present where crystallization transpires. For this study, the solution properties 
(solubilities in aqueous, organic and mixed aqueous-organic solvents) governing each 
pathological disease’s crystallization were scrutinized to elucidate the growth 
environment.  
For malaria, current approaches to identify lead candidates rely on combinatorial 
screening methods employing whole-parasite assays, which are incapable of elucidating 
the effect(s) of inhibitors on hematin crystallization. In this study, a physiologically-
relevant growth medium (mixed aqueous-organic solution) was used to develop a facile, 
robust method of screening compounds that inhibit hematin crystal growth. As 
benchmarks, antimalarials and antibiotics that are commonly used in combination 
x 
therapies were selected. This assay possesses the capability to be used as a high-
throughput platform to screen libraries of compounds as a more streamlined approach to 
identify inhibitors of pathological crystallization. 
For atherosclerosis, the studies attempted to discern the crystal growth mechanism 
using in situ atomic force microscopy (AFM) in a mixed solvent. The surface features 
and polydispersity of cholesterol crystals are facilitated by the growth conditions 
(supersaturation, rate of cooling, etc.); therefore, bulk crystallization of cholesterol in the 
absence and presence of bile salts was performed to illustrate how natural compounds 
affect crystallization.  
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Chapter 1: Introduction 
Crystallization is a natural phenomenon occurring in a variety of environments 
ranging from the atmosphere to the core of the earth to inside the human body. The 
environment in which a crystal develops is important for its structure, growth rate, 
mechanism of formation, and morphology. The understanding of how environments 
affect crystallization is imperative in pathological diseases where crystallization is an 
integral process, such as kidney stones,1,2 gallstones,3,4 atherosclerosis,5,6 and malaria.7,8 
For all of these maladies, crystallization is an undesired activity where pharmaceuticals 
or surgical techniques are required to eliminate the condition. When attempting to 
discover or design new pharmaceuticals for these diseases, it is essential to comprehend 
how the crystallization processes transpire and the effect of the growth environment.  
1.1 Mechanisms of Crystal Growth 
When crystals grow from solution, there are a variety of different pathways by 
which this can occur as seen in Figure 1.9 All of these can be categorized into two broad 
classifications: classical and nonclassical.  
 
Figure 1: Illustration of the numerous routes for crystallization to proceed from simple building blocks to a 
bulk crystal.9  
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1.1.1 Classical Crystallization 
In classical crystallization, growth occurs by monomer-by-monomer addition 
from the solution to the crystal surface.10 A Kossel crystal is the general shape of a basic 
cubic crystal represented as stacked blocks. The surface of a Kossel crystal (Figure 2) has 
specific features where monomer attachment occurs: terraces, steps, and kinks.11 Terraces 
are the flat surface areas between step edges; steps are the separate layers of monomers 
propagating across the surface; kinks form where the step edge is unfinished with half of 
the neighboring bond sites empty.  
 
Figure 2: Schematic of Kossel crystal specifically illustrating the surface features of terraces, steps and 
kinks where solute attachment ensues.12 
 
On the surface of the crystal, there are five important sites where monomers will 
attach as shown in Figure 3: (1) vacancy in a terrace/face, (2) hole in a step, (3) kink, (4) 
step edge, and (5) directly to terrace or face. Monomer incorporation is more 
energetically favorable based on the number of bonds between the crystal and solute. If 
there is a vacancy or hole in a terrace or an edge, monomer addition would leave the least 
number of dangling bonds at one or two. However, the likelihood of a monomer attaching 
directly into those specific sites is low. The most likely sites for attachment are kinks. For 
kink sites, three monomer-crystal bonds are produced and the surface free energy of the 
crystal is unaltered as the kink site is regenerated. The degree of supersaturation 
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surrounding the crystal interface is the driving force behind monomer addition. The rate 
of growth is proportional to the supersaturation. The slowest growing faces of a crystal 
determine the bulk crystal habit. Overall, both kinetic and thermodynamic driving forces 
govern the final crystal habit and size, which are influenced by growth conditions: 
solvent, supersaturation, time, temperature, modifiers, etc.13 
 
Figure 3: Five sites for monomer attachment in classical crystallization. 
 
When a monomer attaches to a surface, there are two modes (Figure 4) by which 
it can transpire: direct incorporation and surface diffusion. In direct incorporation, a 
molecule in solution binds to a kink, step or terrace. Alternatively for surface diffusion, 
attachment to a kink, step or terrace occurs after the molecule first absorbs to the crystal 
surface and diffuses to a growth site for further integration.14  
 
Figure 4: Methods of monomer addition to a crystal surface – surface diffusion and direct incorporation. 
 
Classical crystal growth typically occurs by either a 2-dimensional (2D) layered 
mechanism or from a dislocation.15 In 2D growth, new layers nucleate from 2D nuclei 
and propagate across the surface by addition of monomers illustrated by the schematic in 
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Figure 5.16 During the crystallization of water into ice,17 new layers nucleate as islands as 
shown in Figure 6a.  
 
Figure 5: Diagram of two-dimensional nucleation and layer propagation on a crystal surface.16 
 
The more common method for classical crystal growth is the formation of hillocks 
emanating from a dislocation source18 (Figure 719) or a combination of both 2D and 
dislocation.15 A partial shifting of planes causes a linear defect resulting in an edge or 
screw dislocation. In Figure 6b-e,15,20-23 a variety of crystals growing from a dislocation 
source can be observed. 
 
Figure 6: Examples of crystals with 2D or screw dislocation growth mechanisms. (a) 2D nucleation of ice 
crystals,17 screw dislocations on (b) L-cysteine crystal,20 (c) calcium oxalate monohydrate crystal, 
(d) calcite crystal,21 (e) insulin crystal,22 and (f) ferritin crystal with 2D nucleation.15 
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Figure 7: Schematics of a screw dislocation and how the unit cell orients for this configuration.19 
 
 
1.1.2 Nonclassical Crystallization 
For nonclassical crystal growth, monomers form higher order oligomers, 
amorphous or nanocrystalline particles in solution and attach to the surface furthering 
crystallization. These oligomers, amorphous or crystalline particles serving as growth 
units are termed precursors. Precursors vary with respect to microstructure, size, shape 
and state of matter.24-26 For oligomers, it follows a similar pathway of crystal growth as 
classical crystallization for monomers as shown in Figure 8.12	  	  
 
Figure 8: Pathways for classical crystallization and nonclassical crystallization demonstrating how 
precursors are developed in solution before addition to the surface.12  
 
Gels or liquid-like aggregates can form when monomers or oligomers are loosely 
connected.9 If monomers or oligomers bond covalently, they materialize into amorphous 
particles or bulk solid aggregates. After attachment, precursors undergo a transition from 
disordered to ordered.27 This transition is necessary for the particles to fully rearrange and 
integrate into the crystal lattice structure. A few examples of crystals, which grow by 
nonclassical crystallization, are shown in Figure 9.12,27-29 
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Figure 9: Examples of nonclassical crystallization in zeolites: (a) silicalite-1,27 (b) LTL,28 and (c-d) SSZ-13 
or CHA.12,29 
 
1.2 Modifiers in Solution 
Modifiers are regulators of crystallization capable of changing the crystal 
morphology, size, suppressing or promoting growth.30,31 They can range from ions to 
macromolecules, such as polymers or proteins. Both classical and nonclassical 
crystallization pathways are affected by the presence of modifiers, possessing different 
mechanisms.32-34 
1.2.1 Classical Modes of Growth Inhibition 
In classical crystallization, the effect of modifiers can be explained by type of 
species attachment and the location on the crystal surface. There are three proposed 
mechanisms for types of inhibition based on the type of species attachment (Figure 10): 
(i) the solute could form a complex with the inhibitor and block crystal growth by 
binding to the surface; (ii) a solute/inhibitor complex does not bind the crystal surface, 
altering the degree of supersaturation slowing growth; and (iii) the inhibitor could bind 
directly to the crystal surface causing inhibition.35 
 
Figure 10: Three proposed mechanisms of inhibition based on type of species attachment. 
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On the crystal surface, modifiers can bind to kinks, steps and terraces. In the step 
pinning mechanism, modifiers attach to crystal terraces and impede further propagation 
of steps.36 As steps advance and chance upon a modifier on a terrace, the step velocity 
decreases due to strain imposed. If two or more modifiers are spaced on a terrace close 
enough, the step propagation will be fully arrested as seen in Figure 11a.12  
For kink blocking mechanism, modifiers bind to kink sites on the crystal surface 
shown in Figure 11b.12 This attachment decreases step velocity due to blocking the most 
energetically favorable site for monomer addition.13 Depending on the concentration of 
modifier attachment to kinks, step advancement can be fully suppressed or significantly 
reduced. 
Larger modifiers can cause macro-step induction or bridging. In this case, the 
modifier binds to a step edge and the terrace above the step. This causes macro-steps to 
form and step velocity to decline.37  
Another mechanism, shown in Figure 11c-d,12 behaves similar to the kink 
blocking mechanism, but can cause dissolution of crystal surfaces under certain 
conditions by inducing localized strain.21 This mode of action is not fully resolved yet 
and only works for specific range of concentrations; if the concentration is too low or 
high, it will revert to kink blocking or competitive attachment/detachment of monomers 
leading to non-uniform attachment and disappearance of distinct layers, respectively.	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Figure 11: Modes of inhibition for classical crystallization: (a) step pinning, (b) kink blocking, and (c-d) 
strain induced dissolution.12  
 
1.2.2 Inhibition of Nonclassical Crystallization 
In nonclassical crystallization, there are no specific crystal surface binding sites 
for modifier attachment.9 However, modifiers can alter monomer, oligomer or precursor 
attachment, speciation reactions, self-assembly of amorphous particles and structural 
evolution of precursors. On the surface, the transition from disordered to ordered can also 
be hindered. The modifier can complex with oligomers in solution or stabilize precursors 
to prevent aggregation and attachment to crystal surfaces. Overall for nonclassical 
crystallization, there are a plethora of pathways for inhibition.27,29,38 
1.3 Crystallization of Hematin 
Malaria is a mosquito-borne parasitic infectious disease caused by five species of 
parasites of the genus Plasmodium (falciparum, vivax, malariae, knowlesi, and ovale).39 
While significant public health efforts have eradicated malaria from North America, 
Europe, and other well-developed regions of the world, the disease is endemic in the 
equatorial regions of Africa, South America, Southeast Asia, and Oceania as seen in 
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Figure 12 with approximately 40% of the global population is at risk for transmission, 
200 million episodes occurring annually and 600,000 episodes resulting in deaths.40 
 
Figure 12: World map illustrating areas where malaria is prevalent.40 
 
The pathophysiology of malaria is complex, but relies on crystallization for the 
survival of parasites. The life cycle of the malaria parasite in the human body consists of 
multiples stages shown in Figure 13.41 When a human is infected with the parasite via a 
mosquito bite, the parasite travels to the liver where it reproduces asexually, creating 
merozoites.42 The merozoites then relocate to the circulatory system where they infect 
erythrocytes.43 At this stage, merozoites can either reproduce asexually (transforming into 
trophozoites and subsequently schizonts) or develop into immature gametocytes. When a 
mosquito bites a human, it withdraws blood and gametocytes, repeating the cycle again.44 
While in the bloodstream, parasites infiltrate red blood cells and catabolize hemoglobin, 
releasing heme that is oxidized to toxic hematin. The latter is sequestered into innocuous 
crystals called hemozoin. Many antimalarial drugs inhibit the sequestration of heme (i.e., 
hemozoin crystallization), thereby eradicating the parasite from the body due to the 
cytotoxicity of hematin. The full process is illustrated in Figure 14. 
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Figure 13: Schematic demonstrating the life cycle of Plasmodium parasites. (A) Mosquito infects the 
human host where it is circulated throughout the body to reproduce in various stages. (B) 
Heme molecule resulting from catabolization of hemoglobin. 
 
Heme detoxification occurs within the parasite’s digestive vacuole (DV), which is 
a complex environment for crystallization comprised of membrane interfaces, an acidic 
aqueous solution with pH 4.8 – 5.5, and a collection of various neutral lipids.7 The latter 
are mostly mono- and di-glycerides that result from the degradation of the transport 
vesicle membranes that carry hemoglobin into the DV. The lipid nanospheres in the 
digestive vacuole are composed of five different lipids: monopalmitoyl glycerol, 
monostearoyl glycerol, dipalmitoyl glycerol, dioleoyl glycerol, and dilinoleoyl glycerol in 
a ratio of 2:4:1:1:1.45 
 
 
Figure 14: Diagram of hemoglobin catabolization process in the parasite. Hemoglobin is broken down into 
heme, which is unstable, and immediately oxidizes to toxic hematin. Hematin is sequestered 
into innocuous crystals called hemozoin. 
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The traditional Western treatment for malaria, quinine, and its synthetic 
homologues (i.e., chloroquine,  mefloquine, and others) putatively work by blocking 
hematin crystallization.46 Available evidence suggests that artemisinin, another 
antimalarial drug, binds to heme.47 Currently, combination therapies are the suggested 
method for malaria treatment by the World Health Organization. In combination 
therapies, two or more drugs with different modes of action and biochemical targets are 
utilized simultaneously to produce a highly effective treatment.48 For example, an 
antibiotic, such as doxycycline which causes abnormal cell division, and an antimalarial, 
such as quinine which inhibits crystallization of hematin, are administered together to 
eliminate malaria from the body. 
Very disturbingly, a resurgence of the disease throughout the world has occurred 
since the 1960s and 1970s due to the emergence and spread of Plasmodium parasites 
resistant to chloroquine combination treatments.49,50 Delayed parasite clearance has been 
recorded even for the most recent artemisinin-based therapies.51 These processes weaken 
responses to the common antimalarial drugs underscoring the urgent need for research 
into the main processes of the malaria pathophysiology. Thus, improved understanding of 
the mechanism of hematin crystallization is crucial for new drug development.52,53 
To start to comprehend the entire process of crystallization, the project was 
divided into four areas (Figure 15): solution properties, mechanism of crystallization, 
inhibition, and bulk assay. With all of this potential knowledge combined, a platform for 
designing and screening prospective new compounds as antimalarials can be established. 
This work concentrated on the solution properties and bulk assay while others in the 
group, simultaneously, focused on the mechanism of crystallization and inhibition. 
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Figure 15: Overview of project areas for experimentation. 
 
Currently, there is a dispute as to the location of crystallization inside the DV of 
the parasite. The possible locations of hemozoin formation in the bulk of the two phases 
in the parasite's DV (aqueous and lipid) and three interfaces (aqueous/lipid, 
aqueous/membrane, and lipid/membrane) are marked in Figure 16: 1—in the bulk of 
aqueous phase, 2—in the bulk of the lipid nanospheres, 3—at lipid/aqueous interface, 
4—at the DV membrane in the lipid phase, and 5—at the DV membrane in the aqueous 
phase.54 The driving force behind crystallization is the solubility of the solute molecule.10 
To ascertain the potential effectiveness of a solvent as a growth solution, the solution 
properties need to be determined.  
 
Figure 16: Schematic illustration of P. falciparum infecting a red blood cell. Spherical agglomerations of 
neutral lipids that are several hundred nanometers in size, referred to as nanospheres, are 
present in the digestive vacuole. 
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 Using the solution properties, the most probable growth environment of hematin 
crystallization can be elucidated after attempts to grow crystals in various conditions of 
each solvent. With this knowledge, another colleague determined the mechanism of 
crystal growth utilizing in situ atomic force microscopy (AFM). In conjunction, she 
introduced a number of current antimalarial drugs to observe their inhibition effects on 
hematin crystallization. 
Assays play an integral role in the discovery of new pharmaceutical drugs for 
diseases.55 With high-throughput assays, companies test libraries of drugs containing 
thousands of compounds to determine their applicability. Current methods for discovery 
of new antimalarials are parasite-based assays, which do not indicate the functionality of 
the compounds whether they act by corrupting the reproductive cycle of the parasite, 
inhibiting crystallization or some other means. To aid in this endeavor, a new biomimetic 
assay was designed to determine the efficacy and potency of antimalarials for hematin 
crystallization. To enhance its utility, it must be adaptable to high-throughput. Such an 
assay will help streamline the process for detection of compounds that should be studied 
further utilizing more extensive methods, such as AFM. 
In Chapter 2, the detailed background of malaria and hematin crystallization 
including initial understanding of the disease, previous methods of crystallization, current 
treatments, resistance of parasites, etc. will be reviewed. 
In Chapter 3, the determination of the solution properties of hematin, current 
antimalarials and antibiotics will be examined. The growth environment will be debated 
and the discovered mechanism of hematin crystallization and inhibition will be described. 
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In Chapter 4, the biomimetic assay of hematin crystallization designed to quantify 
efficacy and potency of antimalarials will be explained. The adaptation to a high-
throughput configuration will be elaborated.  
In Chapter 5, the work on the hematin project and the valuable information 
gleaned from our systematic approach to fundamentally understanding hematin 
crystallization will be summarized. 
1.4 Cholesterol Crystallization 
The gallbladder stores and releases bile made by the liver into the small intestines 
to help digest fats. Gallstones form in the gallbladder when the bile is supersaturated with 
cholesterol or bilirubin.56,57 These are similar to tiny rocks or stones, which can become 
lodged in the ducts transporting bile from the gallbladder as shown in Figure 17. This 
creates blockages resulting in inflammation of the gallbladder, liver and pancreas. In the 
developed world, between 10-15% of the population have gallstones with 1-4% 
developing symptoms annually.58,59 
 
Figure 17: Diagram of the digestive system demonstrating where gallstones form in the gallbladder and 
can cause blockages in ducts. 
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Over 75% of all gallstones are cholesterol based and occur when the liver excretes 
more cholesterol than the bile can dissolve. Bilirubin or black pigment stones account for 
approximately 20% of stones as an effect of liver cirrhosis, biliary tract infections or 
certain blood conditions, which cause the liver to produce too much bilirubin. 
To treat gallstones, there are both nonsurgical and surgical methods.60-63 A 
laparoscopic cholecystectomy is the most common treatment where the gallbladder is 
removed with a minimally invasive surgery. The patient is either released the day of 
surgery or after one overnight stay with only a few days of missed work.64 A nonsurgical 
method for those patients unable to have surgery is dissolution of gallstones with 
pharmaceutical drugs,65 such as ursodeoxycholic acid,66 and only work for cholesterol 
stones. Overall, $6.5 billion is spent annually on gallbladder disease.59 
Cholesterol crystallization not only occurs in gallstones, but also in 
atherosclerosis.67 This is what is commonly known as hardening of the arteries or plaque. 
In this disease, the pathology occurs over decades, starting at adolescence, through 
continuous evolution of arterial wall lesions.68 At the beginning, low-density lipoproteins 
(LDL), which transport lipids or fats around the body, leave the bloodstream and enter 
the innermost coating of the artery, arterial intima, due to an inflammatory response of 
white blood cells.69 As LDL levels increase in the intima, they accumulate; without 
adequate removal of cholesterol and fats from the macrophages by high-density 
lipoproteins (HDL), the build up of cholesterol and fats can lead to blockage of arteries as 
shown in Figure 18. These blockages cause heart attacks, strokes, etc. depending on the 
location.  
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Figure 18: Progression over time of atherosclerosis from a normal artery to when the artery becomes 
blocked by the plaque formed. 
 
Heart disease is the number one killer of men and women in the United States. 
Every year, about 700,000 Americans suffer from heart attacks and 130,000 die from 
strokes.70 Most people do not realize they have the disease until it is too late. The 
estimated costs associated with coronary heart disease in the United States are $100 
billion.71 One major preventative medicine is a group of pharmaceuticals called statins.72 
These drugs help by decreasing the amount of cholesterol produced by the liver, which 
accounts for 70% of the cholesterol in the body. In 2013, $35 billion was spent on 264 
million statin or cholesterol treating medication prescriptions with 25% of Americans 
over the age of 45 taking some type of statin.73,74 
 For both of these diseases, the knowledge is limited on the mechanism of 
cholesterol crystallization and how current medications, such as bile salts, affect this 
process. To create potential new medications to cause dissolution of cholesterol crystals 
in plaques and gallstones, it is imperative to understand the fundamentals. 
For this project, the same strategy utilized for the hematin project was 
implemented by subdividing the aspects into the same four categories as shown in Figure 
15: solution properties, mechanism of crystallization, inhibition and bulk assay. By 
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attacking this problem at all of these levels, an overall understanding of the entire system 
can be developed. 
 
Figure 19: Diagram depicting the environments of the gallbladder and arteries where both aqueous and 
lipid media are present. 
 
The environment present in both the gallbladder and arteries contains both lipid 
and aqueous media similar to the hematin project and the parasite DV. In the gallbladder, 
bile is stored which is composed of more than 90% water with lipids.75 The lipid species 
are bile salts (67% of solutes by weight), phospholipids (22%) and cholesterol (4%).57 
Cholesterol accumulates in phospholipids in the gallbladder due to its low solubility in 
water.76 In the arteries, blood contains blood cells suspended in blood plasma. Plasma 
accounts for 55% of the blood and is comprised of 92% water and 8% blood plasma 
proteins.77 It also includes serum albumin, lipoproteins, antibodies, electrolytes, minerals, 
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and other proteins. For both systems, cholesterol crystallizes in a lipid environment as 
shown in Figure 19. 
Initially, a variety of solvents were examined to decide which ones would be the 
most beneficial as a mimic for pathological crystallization. For each of these solvents, the 
solution properties and the effects of the addition of water were determined. This 
knowledge enabled a suitable solvent to be chosen as the best option for attempting to 
ascertain the mechanism of crystallization.  
After selection of the solvent, AFM was utilized to study the surface of 
cholesterol crystals. Determination of the growth mechanism of cholesterol crystals and 
how bile salts and other medications inhibit crystallization were the main goals of this 
effort. Bulk crystallization studies were performed simultaneously to understand the best 
method for crystallization and the effects of bile salts on the morphology, aspect ratio, 
and nucleation. 
In Chapter 6, the current understanding of atherosclerosis and gallstone formation 
will be reviewed. The current medications available for each disease and common 
surgical procedures performed will be explained. 
In Chapter 7, the solution properties of cholesterol in aqueous and organic 
solvents and how water affects these will be examined. 
In Chapter 8, bulk crystallization of cholesterol crystals will be explained along 
with how different factors affect this crystallization process. The efforts of uncovering 
the growth mechanism of cholesterol crystals will be addressed. The correlation between 
known crystal structures and measurements made on the surface of crystals will be 
discussed. The effects of bile salts will be shown. 
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In Chapter 9, the conclusions and summary of this project will be illuminated and 
how others can build upon the knowledge gained in these studies. 
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Chapter 2: Pathophysiology of Malaria 
Malaria has been around for centuries causing loss of life dating back all the way 
to records in 2700 BC in China. However it was not until 1880 when Charles Louis 
Alphonse Laveran published a paper about his discoveries while examining a fresh 
unstained blood sample from a soldier in Algeria, the world began to truly understand 
what type of disease it was battling. He found motile pigmented bodies which he 
categorized as a parasitic organism.78 However, his efforts went unnoticed at the time due 
to theories of a type of bacteria (bacillus) or unpleasant stench (miasma) as the culprits of 
malaria. Another four years had to pass before Ettore Marchiavava and Angelo Celli 
examined live, unstained specimens rather than stained, dead ones. It was at this time 
they rediscovered the etiology of malaria and named the parasite P. malariae. Over the 
next ten years, researchers correlated the periodicity of human symptoms to the life cycle 
of parasites and determined the existence of multiple species of parasites causing malaria. 
In humans, malaria is caused by five different species of Plasmodium parasites: P. 
falciparum, P. malariae, P. ovale, P. vivax, and P. knowlesi.79 The most common species 
found in humans is P. falciparum at approximately 75% with P. vivax accounting for the 
second most with roughly 20%. Most of the recorded deaths are African children from P. 
falciparum. P. vivax is more common outside of Africa, especially in South America. 
2.1 Signs & Symptoms 
After infection with the parasite, the signs and symptoms appear after 8-25 days. 
For those who travel to malaria transmission regions of the world and take preventative 
medication, the symptoms may take longer to develop. Initially, malaria resembles the flu 
and other diseases with headaches, fever, shivering, joint pain, vomiting, jaundice, 
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hemoglobin present in the urine, hemolytic anemia, retinal damage and convulsions.79 A 
classic sign of malaria is a cycle of sudden coldness followed by shivering then 
subsequent fever and sweating, called paroxysm, every two or three days depending on 
the type of malaria. 
Once infected, the body recognizes erythrocytes that contain parasites. The spleen 
filters the red blood cells and removes those infected. To prevent removal from the body, 
the parasite displays adhesion proteins on the surface of red blood cells to stick to the 
walls of blood vessels.80 As a result of this, the parasite can breach the blood-brain barrier 
causing cerebral malaria. In cerebral malaria, the patient exhibits neurological symptoms 
such as abnormal posturing, nystagmus (involuntary eye movement), opisthotonus 
(arching of the spinal column), conjugate gaze palsy (inability of eyes to turn together in 
the same direction), seizures or coma.81  
2.2 Diagnosis & Detection 
Due to the fact that malaria presents similar to the flu, the most common method 
for diagnosis is microscopy and examination of blood films. With blood films, there are 
two types that are traditionally performed: thin or thick films. Examples of images from 
these techniques can be seen in Figure 20.82 
With thin films, the species of parasite infection can be determined as each has 
distinguishing characteristics. Thin films enable preservation of the parasite’s appearance 
during preparation. For thick films, the level of sensitivity is higher and picking up low 
levels of infection are easier. However, the volume is thicker making it difficult to 
distinguish the type of species. With both of these tests, the number of parasites in the 
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blood can be discerned. When monitoring treatment, this knowledge can be essential to 
know how effective a pharmaceutical administered is functioning. 
 
Figure 20: Microscope images of P. falciparum trophozoites on (A-B) thick films and (C-D) thin films.82 
 
 To enhance the detection of parasites in blood films, certain fluorescent dyes 
have been introduced which have an affinity for nucleic acid in the parasite nucleus.83 
The dye attaches to the nuclei and when excited at a specific ultraviolet wavelength, the 
nucleus fluoresces vividly. Depending on the type of dye utilized, it can be more or less 
effective as it may bind to cells other than the parasite nucleus. For example, 
benzothiocarboxypurine (BCP)84 stains red blood cells and leukocytes poorly, but P. 
falciparum strongly as seen in Figure 21.83 
In some areas of the world, microscopy is unavailable or laboratory technicians 
are unqualified. Therefore, other methods have been developed to aid in the diagnosis of 
infection, such as rapid diagnostic tests.85,86 These tests are capable of qualitative results 
in 15-20 minutes and are simple to use. The only downside is the threshold of detection is 
100 parasites/µL of blood compared to 5 in thick blood films. 
A B 
C D 
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Figure 21: Fluorescence image of P. falciparum trophozoites stained with BCP.83 
 
One popular device is the immunochromatographic test, which relies on the 
diffusion of a liquid across a nitrocellulose membrane. Monoclonal antibodies are 
attached to the membrane to capture parasite antigens from the peripheral blood. In this 
system, there is a mobile phase containing malaria antigen targets conjugated to a 
liposome containing selenium dye or gold particles. These targets form antibody-antigen 
complexes, which migrate across the nitrocellulose membrane. When the complexes 
reach the immobile monoclonal antibodies along the strip, they are captured producing a 
visible line. If there are no parasite antigens, the line will not appear. The strip also 
contains an immobile control antibody, usually a goat anti-mouse monoclonal antibody.87 
The general setup of an immunochromatographic test can be seen in Figure 22. 
Currently, there are three malaria antigens targeted: histidine-rich protein 2 (HRP-
2),88 Plasmodium lactate dehydrogenase (pLDH),89 and Plasmodium aldolase.90 HRP-2 is 
a water-soluble protein produced by asexual stages and gametocytes of P. falciparum. 
Despite its abundance and usefulness, not all species of Plasmodium parasites produce 
this protein. Therefore, it is only suitable for detection of P. falciparum. pLDH is an 
enzyme produced in the glycolytic pathway of the malaria parasite at both the asexual 
and sexual stages. Four species of the parasite produce this enzyme in various isomeric 
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forms, making it more effective at qualitatively determining whether one is infected with 
malaria. If both a non-species specific monoclonal antibody and P. falciparum specific 
monoclonal antibody are attached to the membrane, the patient can verify whether they 
have the most common type of malaria or one of other forms. However, if a patient is 
infected with multiple types of malaria, the test will only indicate one as they have the 
same antibody targets. Aldolase is another enzyme produced by glycolytic cycle of the 
parasite similar to pLDH. 
 
Figure 22: Schematic of immunochromatographic test for simple determination of malaria diagnosis. The 
results are qualitative and will not be able to indicate effectiveness of treatments. 
 
2.3 Attempts to Eradicate Malaria & Treatments 
In 1894, Sir Ronald Ross became interested in malaria parasites after Patrick 
Manson showed him parasites in the human bloodstream. He set out to prove the theory 
by Manson and Laveran that the propagation of malaria was connected to mosquitoes. 
After two years, Ross made his landmark discovery of malaria parasites in the stomach of 
an anopheline mosquito after feeding on a human infected with malaria four days 
previously. Over the next year, he utilized birds to demonstrate a cycle of malaria 
transfer. After the mosquitoes feasted on the birds, they were infected with bird malaria, 
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which eventually migrated to their salivary glands enabling the mosquitoes to infect more 
birds. 
2.3.1 Removal of Mosquitoes 
After this monumental discovery, Ross switched his focus toward prevention of 
malaria through disruption of the parasite life cycle at the mosquito stage. His thoughts 
were if there were no mosquitoes, there would be no transmission. Others suggested that 
instead of killing all mosquitoes, but rather only target the ones that transmit malaria. For 
most of the 20th century, the efforts to combat and control malaria focused on mosquito 
eradication.  
Between World War I and World War II, the League of Nations and its committee 
dedicated to malaria was established.78 The main goal was to investigate means to 
remove mosquitoes from malaria regions of the world. In 1939, Swiss scientist Paul 
Hermann Müller discovered the insecticidal properties of 
dichlorodiphenyltrichloroethane (DDT), whose structure can be seen in Figure 23. During 
World War II, DDT was utilized extensively to limit the havoc wrecked upon soldiers in 
the South Pacific by malaria and dengue fever.91 This successful application of DDT 
inspired newly founded World Health Organization (WHO) to start antimalarial crusades. 
By 1955, this evolved into a global eradication campaign based on antimosquito efforts.92 
However, this only succeeded in developed countries. Malaria was eliminated from 
Taiwan, the Balkans in Europe, much of the Caribbean, parts of northern Africa, northern 
region of Australia and some of the South Pacific during this time. Over time, a 
resurgence of malaria in certain areas occurred to due to an increase in mosquito 
resistance to DDT, increasing parasite tolerance and a failure to sustain the program.93 In 
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sub-Saharan Africa where malaria transmission is highly stable and infection severe, the 
spraying of DDT was ineffective due to poor infrastructure and continuous life cycle of 
mosquitoes. In reality, the program only succeeded in eradicating malaria from areas with 
high socio-economic status, an organized healthcare system, and seasonal or relatively 
low intensity malaria transmission. In 1969, the idea of eradication was abandoned and 
attention shifted to control and treatment of malaria. 
 
 
Figure 23: Molecular structure of insecticide used in attempts to eradicate mosquitoes and malaria. 
 
The impact of the eradication program had other effects besides elimination of 
mosquitoes. As DDT was more extensively used, the environmental impact of excessive 
spraying was realized. DDT is readily absorbed by aquatic organisms, which propagated 
through the food chain to birds. Accumulation of DDT in birds, due to its lipophilic 
properties, resulted in a decrease in populations from inability to produce proper eggshell 
thickness. It is also toxic to a variety of marine animals, such as crayfish, sea shrimp and 
a variety of fish. For humans, DDT is an endocrine disruptor and is classified as 
“moderately toxic” or “moderately hazardous” by the U.S. National Toxicology Program 
and WHO, respectively. As a result, banning of DDT began in 1968 in Hungary followed 
by Norway and Sweden in 1970, West Germany and the United States in 1972, with 
others following suit over the next two decades. By 1991, 26 countries had total bans 
over the use of DDT. Eventually, in 2001 at the Stockholm Convention on Persistent 
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Organic Pollutants, DDT was restricted to vector control with exemptions for public 
health based on the WHO guidelines. 
2.3.2 Antimalarial Drugs 
Over the years, numerous medications have been employed to combat malaria. 
Each pharmaceutical compound attacks a distinct life cycle process of the parasite 
including: tissue schizonticides for prophylaxis, blood schizonticides, tissue 
schizonticides for relapse prevention (P. vivax and P. ovale), gametocytocides and 
sporontocides.94 Table 1 elaborates on these categories of antimalarial activity and lists 
various drugs that interrupt these life cycle processes. Within these categories, various 
chemical targets are possible. A general approach to malaria treatment, recommended by 
The World Health Organization,40 involves combination therapies. In this approach, two 
or more drugs with different modes of action and biochemical targets are applied 
simultaneously to produce a highly effective treatment. 
Table 1: Categories of Antimalarial Activity 
2.3.2.1 Quinine (QN) 
One of the first natural antimalarial drugs discovered was quinine (QN) from the 
tree bark of the cinchona trees indigenous to South America.95 The Quechua people 
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would ground the bark up and mix with sweetened water, producing tonic water, to act as 
a muscle relaxant. The Jesuits were the first to transport cinchona to Europe. In 1631, it 
was used to treat malaria in Rome where it was endemic during the 17th century. Malaria 
had been responsible for the death of several popes, many cardinals and countless 
citizens. The drug became popular in London after King Charles II consumed quinine to 
cure himself of malaria. Quinine was the drug of choice to treat malaria until the 1940s 
when others were synthesized. 
Prior to 1820, the bark of the cinchona tree was dried, ground into a powder, then 
added to a liquid to be taken orally. Pierre Joseph Pelletier and Joseph Caventou 
extracted, isolated and name the compound quinine from the bark in 1820.96 Around 
1850, quinine began large-scale usage as a preventative medicine. Quinine was not 
successfully synthesized until 1918, but the process was elaborate, expensive and yielded 
low quantities with the additional problem of stereoisomers. Therefore, production is 
based on extraction from cinchona trees even today. 
In the bark of the cinchona tree, there are other similar compounds (quinidine, 
cinchonine, and cinchonidine) effective against malaria. The efficacies of these four 
compounds were measured from 1866 to 1868 in clinical trials from 3600 patients. In this 
trial, they monitored the paroxysm symptoms and found a greater than 98% cure rate for 
all four compounds. However, after 1890, quinine was the predominant drug used based 
on supply concentration from the bark, which was harvested from other locations in the 
world besides South America.95 
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Quinine is an alkaloid molecule, which can be seen in Figure 24. Due to its 
extremely basic nature, it is always presented as a salt. Preparations include 
hydrochloride, dihydrochloride, sulfate, bisulfate, and gluconate salts.  
 
Figure 24: Molecular structure of antimalarial quinine. 
 
Overall, the antimalarial mechanism of action is unknown at the present time. It 
does possess rapid schizonticidal action against intra-erythrocytic malaria parasites and 
where it is hypothesized it interferes with the crystallization process of hemozoin. In P. 
vivax and P. malariae parasites, it also acts as a gametocytocide. After administration 
orally or intravenously, the body rapidly absorbs quinine reaching peak concentration 
after 1-3 hours.97 It distributes throughout the entire body including cerebral spinal fluid 
and across the placental barrier with a half-life of 11-18 hours. 
While quinine is effective against malaria, it has a low therapeutic index. The 
therapeutic index of drug is the comparison of the amount of the compound that causes 
the minimum therapeutic effect versus the amount that causes toxicity. Quinine is known 
to have serious side effects if dosed inappropriately. When quinine is administered at 
therapeutic levels, the side effects are referred to as cinchonism which include: flushed 
and sweaty skin, ringing of the ears, blurred vision, impaired hearing, confusion, 
headaches, abdominal pain, rashes, vertigo, dizziness, nausea, vomiting, and diarrhea. 
Very rarely, it can cause death and paralysis if injected into a nerve. 
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Nowadays, other medications have become the main course of treatment against 
malaria instead of quinine. It is now used as a second line treatment in combination with 
an antibiotic for uncomplicated malaria if the first line treatment does not work or is 
unavailable. However, in the case of severe malaria, quinine remains the main treatment 
method as it requires quick, safe and effective intravenous drugs. 
2.3.2.2 Chloroquine (CQ) 
In 1934, Johann Andersag and his coworkers at Bayer laboratories discovered a 
new compound, which they called Resochin, as a substitute for quinine; they synthesized 
and tested approximately 12,000 compounds in this process. It is chemically similar to 
quinine in that they both possess a quinoline base structure, which can be visualized in 
Figure 25. Resochin went relatively unnoticed for a decade as it was believed to be too 
toxic until World War II when the United States government sponsored clinical trials. At 
this time, the impact of the new compound would be fully revealed; it was undeniably 
effective as an antimalarial with the added benefits of being cheap to produce and fewer 
side effects than quinine. In 1946, it was officially named chloroquine (CQ). 
Chloroquine functions as a blood schizonticide and against P. vivax and P. 
malariae as a gametocytocide analogous to quinine. The mechanism of antimalarial 
action is believed to inhibition of crystallization of hematin causing toxic levels of 
hematin to accumulate in the parasite. Another potential idea is it interferes with the 
biosynthesis of parasite nucleic acids. It is administered orally and diffuses into the 
body’s adipose tissue with a high volume of distribution. The half-life is longer at 1-2 
months, but the side effects are minimal with gastrointestinal problems, itches, 
headaches, postural hypotension, nightmares and blurred vision. The therapeutic index 
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for chloroquine is narrow and improper dosages can occur. When an overdose occurs, the 
patient can experience headache, drowsiness, visual disturbances, nausea, vomiting, 
cardiovascular collapse, seizures and sudden respiratory and cardiac arrest. 
 
Figure 25: Structures of quinoline and antimalarial chloroquine. The group of antimalarials commonly 
utilized to inhibit hematin crystallization has a quinoline base structure. 
 
In the late 1950s, the first documented case of P. falciparum resistance to 
chloroquine was reported in Colombia and at Cambodia-Thailand border. Over the next 
decade, the resistance of malaria spread steadily across South America and Southeast 
Asia.98 In the 1970s, chloroquine-resistant malaria finally appeared in Africa and 
subsequently, dispersed across the continent over the next decade. P. vivax remained 
susceptible to chloroquine until 1989 when resistance was discovered in Papua New 
Guinea. Due to this resistance, other antimalarials were necessary for treatments as the 
morbidity and mortality of malaria resurged.  
2.3.2.3 Artemisinin (ART) 
During the time of emerging antimalarial resistance, the government of the 
People’s Republic of China embarked on a systemic endeavor to discover if any 
indigenous plants used in traditional remedies possessed specific compounds to act as 
pharmaceuticals.99 One plant, known as qing hao (or Artemisia annua L., sweet 
wormwood, annual wormwood), had been documented as a potential antimalarial as it 
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combats the fever and chills associated with malaria in 1596 by a herbalist, Li Shizhen.100 
Initial attempts to ascertain its capabilities as an antimalarial were unsuccessful with a hot 
water extract. However, a researcher, Tu Youyou, tested low temperature extraction with 
ethyl ether in 1971 with a profound difference in potential efficacy. Further purification 
of antimalarial fractions lead to the recovery of a plant constituent that never been 
reported in 1972. This new compound was named qinghaosu or artemisinin, ART, 
(Figure 26), but these results were not published until 1979. Initially, artemisinin was 
believed to be too unstable to be an effective antimalarial, but by 2006, artemisinin 
combined with other antimalarials was designated by WHO as the suggested treatment of 
choice for malaria.  
 
Figure 26: Molecular structure of antimalarial artemisinin. 
 
Artemisinin is a sesquiterpene endoperoxide antimalarial that inhibits the 
development of trophozoites functioning as a blood schizonticide. It is has also been 
reported to act as a gametocytocide.101 For artemisinin, the antimalarial activity is 
dependent upon the endoperoxide bridge in its structure and cleavage of this bridge 
produces an activated form.102,103 Intraparasitic heme or iron may react with artemisinin 
to cleave the endoperoxide bridge creating toxic free radicals.104 In this form, there are 
numerous ways artemisinin can function as an antimalarial: inhibit crystallization of 
hematin, protein alkylation, or interaction with membrane containing structures.105,106 
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Figure 27: Chemical structures of four common derivatives of artemisinin which are prescribed to treat 
malaria. 
 
The physical properties of artemisinin limit its efficacy as an antimalarial. It has 
poor bioavailability; therefore, several semisynthetic derivatives have been manufactured 
including artesunate, artemether, dihydroartemisinin, and artelinic acid to improve 
solubility in either aqueous or lipid media (Figure 27). The half-life of artemisinin is on 
the order of an hour, requiring daily doses over several days.107 Normally, artemisinin is 
not used as a lone treatment due to recrudescence. It is paired with another antimalarial 
possessing a longer half-life. While artemisinin is extremely effective, it is much more 
expensive than chloroquine and limits its availability to those infected as most live in 
poverty.108 
In 2008, strains of artemisinin resistant malaria emerged in western 
Cambodia.109,110 Resistance to artemisinin-based therapies is spreading to other areas in 
Southeast Asia and Africa.111,112 Unregulated use of artemisinin based therapies, poor 
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quality artemisinin based therapies with sub-therapeutic quantities, and widespread 
availability and use of artemisinin lead to the development of resistant parasites.113  
2.3.2.4 Other Antimalarial Drugs in Use 
During this same time, other antimalarials were discovered or synthesized as 
replacements due to resistance of parasites.114 Antibiotics were utilized in attempts to 
help limit the occurrence of resistance in combination therapies with other antimalarials. 
Table 2 is a summary of common pharmaceutical compounds in use for treatments 
against malaria. For all of the drugs in the table, parasites demonstrate resistance in some 
form. 
Table 2: Common Antimalarials and Their Applicability	  
Drug Structure Life Cycle 
Target 
Hypothesized 
Mechanisms 
Usefulness 
Amodiaquine 
[AQ]115 
 
Blood 
schizonticide 
Inhibit 
hematin 
crystallization 
Second cheapest 
drug to produce; 
Only used in 
Africa 
Mefloquine 
[MQ] 
 
Blood 
schizonticide 
Complexation 
between 
mefloquine 
and hematin 
for 
crystallization 
inhibition 
Long half-life (2-4 
weeks); Taken 
prior to traveling 
to malaria 
endemic regions 
Sulfadoxine 
[SX] 
 
Blood 
schizonticide 
Interferes 
with folate 
synthesis 
disrupts DNA 
replication, 
cell division 
and 
reproduction 
Half-life 7-9 days; 
Combined with 
Pyrimethamine 
usually 
Doxycycline 
(Tetracyclines) 
[DC] 
 
Tissue 
schizonticide – 
prevention; 
Blood 
schizonticide 
Targets 
apicoplasts in 
parasites 
Cheap and 
effective drug 
used in 
combination with 
another 
antimalarial with 
hematin 
crystallization 
inhibition; slow 
onset 
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Table 2 continued 
Drug Structure Life Cycle 
Target 
Hypothesized 
Mechanisms 
Usefulness 
Pyronaridine 
[PY] 
 
Blood 
schizonticide 
Inhibits 
hematin 
crystallization 
Long shelf life; 
long post-
treatment 
prevention 
Pyrimethamine 
 
Tissue 
schizonticide – 
prevention & 
relapse; Blood 
schizonticide 
Inhibits folic 
acid 
metabolism  
Combined with 
Sulfadoxine 
usually 
Proguanil 
(Chloroguanide) 
 
Blood 
schizonticide; 
Sporontocide 
Inhibits folic 
acid 
metabolism 
Taken daily; 
Prevents 
reproduction of 
parasites 
Atovaquone 
 
Tissue 
schizonticide – 
prevention & 
relapse 
Collapses 
mitochondrial 
membranes 
Used to treat 
malaria in 
developed 
countries 
Halofantrine 
 
Blood 
schizonticide 
Complexation 
to inhibit 
hematin 
crystallization 
Unreliable 
adsorption; Used 
minimally overall, 
mostly 
severe/resistant 
malaria 
Primaquine 
 
Tissue 
schizonticide – 
prevention & 
relapse; 
Gametocytocide; 
Sporontocide 
Block 
oxidative 
metabolism 
Only drug 
affecting certain 
life cycles of 
parasite 
Piperaquine 
 
Blood 
schizonticide 
Inhibit 
hematin 
crystallization 
Slow absorption; 
Long half-life 
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Table 2 continued 
Drug Structure Life Cycle 
Target 
Hypothesized 
Mechanisms 
Usefulness 
Tafenoquine 
 
Tissue 
schizonticide –
relapse; 
Gametocytocide 
Collapses 
mitochondrial 
membranes 
Long half-life (2-3 
weeks); Effective 
against P. vivax; 
improved 
therapeutic index 
 
2.4 Parasite Resistance 
As the Plasmodium parasites became resistant to various antimalarials, it became 
imperative to know why the parasite was able to survive for the implementation of new 
drugs. Would the parasite have immunity against new pharmaceuticals introduced? 
Biologists studied how the parasite mutated and why extremely effective antimalarials no 
longer functioned properly to answer this question. 
For chloroquine, the drug accumulates in the parasite’s digestive vacuole where is 
supposedly interferes with the heme detoxification process. In resistant strains of P. 
falciparum, the concentration of chloroquine inside the digestive vacuole is dramatically 
lower.98 When comparing a chloroquine-resistant strain versus a chloroquine-sensitive 
strain of malaria, the pfcrt gene was identified as a candidate for resistance. The PfCRT 
protein localizes to the digestive vacuole membrane and contains ten putative 
transmembane domains; effectively, this gene determines whether or not an antimalarial 
enters the digestive vacuole. Point mutations in the PfCRT gene enable the parasite to 
survive antimalarials that require entrance into the digestive vacuole including CQ, 
amodiaquine (AQ), mefloquine (MQ), etc. The parasite mutates differently for each new 
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drug launched into use. Different affected genes include: pfcrt, pfmdr1, pftctp, and 
pfmrp1. 
Resistance occurs for antimalarials that do not accumulate in the digestive 
vacuole as well. Both sulfadoxine (SX) and pyrimethamine inhibit part of the folic acid 
synthesis cycle, specifically dihydropteroate synthetase (DHPS) and dihydrofolate 
reductase (DHFR). For sulfadoxine resistance, the DHPS gene mutates while for 
pyrimethamine, the DHFR gene is altered. 
The number of years required for the parasites to mutate and show resistance to a 
drug varies; however, the amount of time is declining. Table 3 compares a variety of 
antimalarials with their dates of introduction and the first reported resistance.116 From this 
table, it can be gleaned that not only is there a need for new antimalarials but also a way 
to understand how antimalarials function to create a platform for pharmaceutical design. 
Since antimalarials are phased out quickly due to resistance, new ones must be available 
to replace them.  
Table 3: Antimalarial Resistance	  
Drug Year Introduced 
First Reported 
Resistance Difference (years) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulfadoxine-
Pyrimethamine 
1967 1967 0 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 0 
 
2.5 Crystal Structure of Hemozoin 
The size and morphology of hemozoin crystals extracted from several 
Plasmodium species has been identified by electron microscopy as shown in Figure 
28.117,118 The hemozoin crystals formed inside of the parasite’s digestive vacuole are 
38 
approximately 100 × 100 × (300-500) nm3 in size. The synthetic crystal β-hematin is 
identical to hemozoin.8	   X-ray diffraction (XRD) has shown that the crystals of both 
hemozoin and β-hematin are triclinic, with space group P1. In both natural and synthetic 
crystals, hematin is present as “head-to-tail” dimers, bound by a coordination bond 
between the carboxyl residues and the Fe 3+ ion.119	  	  
 
Figure 28: Illustration of the crystal structure of hemozoin. (A) Chemical structure of hematin. (B) 
Diagram of β-hematin crystals, packing structure and bonds necessary. (C-E) SEM images of 
crystals extracted from different parasites. (C) P. falciparum (D) S. mansoni (E) H. columbae. 
 
Depending on the solution, hematin will form other types of dimers and 
oligomers, distinct from head-to-tail dimers, including: π–π dimers, in which two hematin 
monomers are in parallel positions, the two Fe atoms face outward, and the monomers are 
linked by overlapping π electron density; µ-oxo dimers, in which two parallel hematin 
monomers are bound by an O atom linking their facing Fe atoms; and larger oligomers, in 
which µ-oxo dimers catenate by π–π linkages. These dimers and oligomers can 
potentially interfere with the process of crystallization. Illustrations of these dimers are 
shown in Figure 29. 
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Figure 29: Structures of hematin dimers. (A) π–π dimers, (B) stacked µ-oxo dimers, and (C) head-to-tail 
dimers found in synthetic and naturally existing hematin crystals. 
 
2.6 Previous Growth Methods 
Attempts to replicate hematin crystallization in vitro have traditionally focused on 
the use of aqueous solvents.120-122 For all procedures in aqueous solutions, the low 
solubility must be overcome otherwise crystallization will not proceed. To improve 
solubility, several methods have been employed (Table 4) including: addition of acetate, 
dimethyl sulfoxide (DMSO), sodium hydroxide (NaOH), introduction of lipid droplets 
and alcohol interfaces.  
When comparing the crystals grown from each environment, there are clear 
difficulties associated with many growth media. If hematin crystallization occurs in 0.1 
M aqueous acetate solution (pH 4.8), the resulting crystals do not possess the morphology 
indicative of hemozoin crystals in vivo.121 The only success at achieving crystals in 
aqueous solutions is through the use of high ionic strength growth media that are not 
physiologically relevant. This suggests that a strictly aqueous environment may not be 
sufficient for hematin crystallization.  Other groups that attempted to form beta-hematin 
crystals in an aqueous environment with lipid droplets succeed at producing crystals with 
the correct morphology.123 Additionally, groups have used DMSO as an organic phase in 
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hematin crystallization; however, DMSO incorporates into the crystal structure.124 These 
results suggest that an organic phase facilitates hematin crystallization. Recently, 
transmission electron micrographs45,125 and X-ray tomography images126 of parasites 
have shown hemozoin crystals seemingly immersed in lipid nanospheres and attached to 
DV membranes coated with lipid.45,126 
Table 4: β-Hematin Crystal Morphology Based on Growth Conditions 
Growth Environment β-hematin Crystals Inconsistencies 
4.5 M acetate, pH 5.0 
 
High ionic strength 
solution – not 
physiologically relevant 
DMSO & water 
 
DMSO incorporates into 
crystal structure 
0.1 M acetate, pH 4.8 
 
Morphology does not 
match crystals found in 
Plasmodium parasites 
monopalmitoyl glycerol 
droplets & water, pH 
4.8 
 
Correct morphology of 
crystals, but lipids are 
expensive and most are 
not liquid are room 
temperature for further 
studies 
 
41 
Table 4 continued 
Growth Environment β-hematin Crystals Inconsistencies 
octanol & water, pH 
4.8127 
 
Correct morphology, 
alcohol substitute for lipid 
blend 
anhydrous octanol  No crystals produced in this solvent 
 
From these previous studies, a starting point can be exposed. Physiologically 
relevant aqueous solutions and purely organic solutions are unable to produce the correct 
morphology crystals or crystals in general. Therefore, the solution properties of 
physiologically relevant environments need to be scrutinized to understand how crystal 
growth may be influenced and proceed.  
 
  
900 nm!
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Chapter 3: Solution Properties Governing Hematin Crystallization 
The crystallization process is heavily dependent upon the growth environment and 
the properties of the solute. For this project, the solution properties of hematin and 
antimalarial drugs are used to shed light on the location of crystal growth of β-hematin in 
the two bulk phases of the DV: aqueous and lipid.  
3.1 Lipid Environment as Growth Medium 
The lipid blend identified within the parasite digestive vacuole is a mixture of five 
neutral lipids: monopalmitoyl glycerol, monostearoyl glycerol, dipalmitoyl glycerol, 
dioleoyl glycerol, and dilinoleoyl glycerol. These lipids are reportedly present in the 
digestive vacuole in a molar ratio of 2:4:1:1:1, respectively.45 The chemical structure of 
the lipids is shown in Figure 30. Only two of the five lipids, dioleoyl glycerol, and 
dilinoleoyl glycerol, are liquid at 25°C.128 To test the phase of the lipid blend, a mixture 
of the five lipids in proportions according to their reported physiological molar ratio was 
prepared. At room temperature the mixture is solid; the melting point of the lipid blend is 
reported at approximately 37°C.129 Thus, it is feasible that this mixture is indeed present 
as a liquid subphase within the parasite DV. The lipid blend is not a practical solvent for 
in vitro tests of hematin crystallization inhibitors owing to the high cost of the 
constituents, the large quantity of lipids required for high-throughput characterization, 
and the inability to perform experiments at room temperature. 
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Figure 30: Chemical structures of five neutral lipids identified in the digestive vacuoles of malaria 
parasites.45 
 
Given the challenges associated with using a lipid blend, our group searched for 
an alternative organic solvent with properties similar to the lipid blend, but one that is 
inexpensive, available in large volume, and liquid at room temperature. To this end, n-
octanol was selected as a surrogate organic solvent. Octanol possesses a long aliphatic 
carbon chain and a polar alcohol group that mimics the amphiphilicity of the lipids. 
Octanol is routinely used to model lipids during determinations of the lipophilicity of 
drugs. Another property of the surrogate solvent that may be significant for hematin 
crystallization is the presence of water. The organic phase in the parasite digestive 
vacuole is in direct contact with an aqueous phase that maintains a pH between 4.8 and 
5.5.130,131 To estimate the amount of dissolved water within the organic subphase, the 
lipid blend was prepared and placed it in intimate contact with water for one hour to 
generate a water-saturated organic phase. The latter was extracted and the solubility of 
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water in the lipid blend was determined using thermogravimetric analysis (TGA). The 
mass fraction of evaporated solvent was recorded as a function of temperature increasing 
from 25 to 120°C. Three different runs with ramp rates, 0.1, 0.3, and 1.0 °C min-1, 
yielded identical results. As shown in Figure 31A, an increase in temperature from 25 to 
85°C results in a loss of mass from the lipid blend, but no further loss was observed 
between 85 and 120°C. An identical study performed with an anhydrous lipid blend 
revealed no mass loss at temperatures lower than 120°C. These temperatures are 
significantly lower than the boiling points of the lipids; therefore, it can be concluded that 
the evaporated compound is water.  
 
 
 
Figure 31: (A) Thermogravimetric analysis of the biomimetic blend of five lipids at a ramp rate of 
0.3oC/min shows the mass loss of water as a function of temperature. (B) Comparison of the 
water solubility in n-octanol (reported by Segatin et al.)132 and the biomimetic lipid blend. 
 
The average amount of dissolved water in the lipid mixture is 8.5 ± 0.5% mass, 
corresponding to a solubility of 4.2 ± 0.3 mol kg-1. In comparison, the water solubility in 
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n-octanol is slightly lower (2.7 mol kg-1), as shown in Figure 31B.132 Previous results 
have indicated that anhydrous n-octanol does not support hematin crystallization.16 
The factors that underlie the need for water in the crystallization solvent are likely 
related to the shared structure of both physiological and synthetic hematin crystals. In 
these crystals, hematin assembles into dimers bound by reciprocal COO–-Fe(III) 
coordination bonds, and connected through chains of -COOH-HOOC- hydrogen 
bonds.133 The formation of hydrogen bonds requires the presence of water and hydrogen 
ions. Hence, as a biomimetic solvent here we use n-octanol as a surrogate for the lipid 
blend, saturate it with citric buffer, and refer to it as CBSO. 
3.2 Hematin Solubility in Aqueous & Organic Environments 
For crystallization to occur, the solvent must be supersaturated with the solute. To 
understand how hematin crystallizes in CBSO in comparison to an aqueous environment, 
the solubility of hematin in CBSO was measured. To determine the solubility of hematin 
in saturated octanol, UV-Vis spectrophotometry and the Beer-Lambert Law,  
A = εbC,     [1] 
where A is the absorbance, ε is the extinction coefficient, b is the path length of the 
cuvette, and C is the concentration of the solute, were utilized. 
As hematin dissolves in either anhydrous or water saturated octanol, a solid 
insoluble residue remains. Hence, hematin concentration in this solvent cannot be 
evaluated from the mass of dissolved material. To transfer known amounts of soluble 
hematin to octanol, hematin was dissolved at a known concentration in NaOH. This 
solution was incubated for two weeks in contact with octanol, as illustrated in Figure 32 
and Figure 33a. Preliminary tests revealed that vigorous stirring led to the formation of 
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emulsions of water in octanol and octanol in water, stabilized by layers of hematin on the 
droplet interfaces; therefore, the aqueous-octanol mixture was only gently stirred at the 
beginning of incubation. Within several minutes after this stirring, the mixture splits into 
two layers with the octanol phase on the top. During the incubation, both water and 
hematin transfer to the octanol phase. The amount of hematin in octanol was determined 
from the difference of the concentrations in NaOH before and after the incubation with 
octanol, as discussed below. 
 
Figure 32: Illustration of experimental procedure to determine the extinction coefficient of hematin in 
water-saturated octanol. 
 
The commercial hematin powder fully dissolves in 0.1 M NaOH. Thus, we used 
its mass to determine the concentration of hematin in this solution. After the exchange 
with octanol, the residual hematin concentration was measured spectrophotometrically. 
To determine the extinction coefficient of hematin in 0.1 M NaOH, solutions with 
varying hematin concentration were prepared. The absorbance spectra of the solutions in 
the 200–800 nm wavelengths range was recorded; an example is displayed in the inset of 
Figure 33c. The dependence of the absorbed intensity at 607 nm on the hematin 
concentration is linear, Figure 33b, and its slope yields the extinction coefficient of 
hematin in 0.1 M NaOH at this wavelength ε =  3.86 ±	 0.06 cm–1  mM–1. 
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Figure 33: Determination of the extinction coefficient of hematin in water-saturated octanol. (a) 20 vials 
with two layers as illustrated in Figure 31. (b) Extinction coefficient of hematin in 0.1 M 
NaOH at 607 nm. (c) Extinction coefficient of hematin in water-saturated octanol at 594 nm. 
 
Finally, the extinction coefficient of hematin in water-saturated octanol was 
determined. Two mL of 0.1 M NaOH solution with varying concentration of hematin was 
placed in 5 ml glass vials. To each vial, 2 mL anhydrous octanol was added and 
equilibrated it for a week at 25oC. The spectra of the octanol and NaOH layers were 
recorded in each vial after filtration through 0.22 µm filters. The hematin spectra in 
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octanol, illustrated in the inset of Figure 33c, exhibit a local absorbance maximum at 594 
nm. The dependence of the absorbed intensity at this wavelength on the hematin 
concentration is linear, Figure 33c, and its slope yields the extinction coefficient of 
hematin in water-saturated octanol, ε =  3.1 ± 0.3 cm−1  mM−1. 
Citric buffer (pH 4.80) was prepared by dissolving citric acid at 50 mM in DI 
water and titrating with 0.10 M NaOH under continuous stirring to the desired pH. The 
buffer was stored with a maximum shelf life of 1 month. Before each experiment, the 
buffer pH was verified. To prepare citric buffer-saturated octanol (CBSO), n-octanol (ca. 
15 mL) was deposited over citric buffer stock solution (5 mL) held in a pre-cleaned 40 
mL glass vial. The resulting two-phase solution was sealed and allowed to equilibrate 
without stirring at 23°C for 30 min. During this time, the organic layer becomes saturated 
with water, forming the CBSO solution. The top CBSO layer was carefully removed with 
a pipette far from the interface to avoid resuspension of the two phases. 
To determine the solubility of hematin in CBSO, 2–5 mM hematin powder was 
added to 5 mL CBSO held in 20-mL glass vials that were subsequently sealed with 
Parafilm. Sets of three vials were stored at four temperatures: 5 °C, 25 °C, 37 °C, and 45 
°C. A 300-µL aliquot was removed weekly from each of the 12 solutions, diluted with 
CBSO, filtered through a 0.22-µm polyethersulfone (PES) filter, and the concentration of 
dissolved hematin was determined spectrophotometrically. This procedure was repeated 
until the concentrations in each vial reached a plateau, defined by three consecutive 
readings of similar value. Microscopic observations revealed that the initial amorphous 
hematin powder appeared to fully dissolve and β-hematin crystals with typical rodlike 
habit had formed. The final steady-state concentrations were averaged over the three 
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samples at each temperature. The resulting mean was used as the solubility ce of hematin 
in CBSO with respect to β-hematin crystals. The data for the four tested temperatures are 
plotted in Figure 34a, where they are compared with a determination using AFM. 
Solubility in AFM studies was determined as the concentration of hematin at the point of 
zero step velocity (i.e., the x intercept in Figure 35). In Figure 34, the solubility of 
hematin in CBSO at 25 °C is compared to that in aqueous citric buffer at the same 
temperature and pH 4.8. 
 
Figure 34: Characterization of the crystal−solution equilibrium from bulk crystallization experiments 
(yellow circles) and by in situ atomic force microscopy (blue squares). (a) The temperature 
dependence of hematin solubility in CBSO. (b) The solubility data in van ’t Hoff coordinates. 
 
Spectroscopic analyses revealed that this solubility is ~105 higher than in aqueous 
buffer at pH 4.8 (Figure 35), which is not surprising given that hematin is a hydrophobic 
molecule. Because crystal growth rates roughly scale with the solubility, this disparity in 
the magnitude of hematin solubility indicates that crystallization from an organic phase is 
a significantly faster method of heme detoxification than from an aqueous phase.13 
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Figure 35: Comparison of the solubility of hematin in citric buffer saturated octanol (CBSO) and aqueous 
citric buffer, pH 4.8 at 25oC. 
 
A dependence of hematin solubility c
e
 in CBSO on temperature is presented in 
Figure 34a. The data in Figure 34 reveal excellent agreement between the solubility 
measured by two separate techniques: bulk crystallization and in situ AFM. To evaluate 
the standard enthalpy ∆𝐻!"#$%!  of hematin crystallization in CBSO, it is noted that, in the 
crystallization equilibrium, 
hematin (solution) ⇆ hematin (crystal),   [2] 
the product is a solid phase and has activity of one. The activity of the soluble hematin 
was assumed to be equal to its concentration. This assumption is justified by the low 
values of the solubilities in Figure 34 that correspond to long intermolecular separations, 
at which the intermolecular interactions are weak and the activity coefficients are near 
unity. With this, the equilibrium constant for crystallization is  
K
cryst
 = c
e
–1
 .     [3] 
The temperature T dependence of solubility c
e
(T) is given by the classical van’t Hoff 
equation 
             
!"#!!!(! !) = ∆!!"#$%!! ,     [4] 
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where R is the universal gas constant. The slope of the c
e
 data plotted in van ‘t Hoff 
coordinates ln c
e
 as a function of (1/T) in Figure 34b yields ∆𝐻!"#$%! = −37 ± 8 kJ mol–1. 
The solubility data can also be used to determine the Gibbs free energy of 
crystallization  ∆𝐺!"#$%!  and the crystallization entropy  ∆𝑆!"#$%! . ∆𝐺!"#$%!  is related to the 
crystallization equilibrium constant K
cryst
 as 
     ∆𝐺!"#$%! = −𝑅𝑇  𝑙𝑛𝐾!"#$% = 𝑅𝑇  𝑙𝑛𝑐!.   [5] 
Equation 5 yields ∆𝐺!"#$%!   = −22 ± 3 kJ mol–1 at 25 °C. The difference between ∆𝐻!"#$%!  
and ∆𝐺!"#$%!  provides an estimate for ∆𝑆!"#$%!  
         ∆𝑆!"#$%! = (∆𝐻!"#$%! − ∆𝐺!"#$%! ) 𝑇.   [6] ∆𝑆!"#$%!  = −49 ± 7 J mol–1 K–1 was obtained. 
The crystallization entropy reflects the loss of translational and rotational degrees 
of freedom when a molecule from the solution incorporates into a crystalline lattice, 
partially balanced by the gain of vibrational degrees of freedom of the newly established 
crystal contacts. The molecular processes underlying ∆𝑆!"#$%!  are similar to those during 
the entropy loss of a molecule binding to another molecule. Estimates of the latter 
process for molecules with sizes similar to that of hematin yield ∆𝑆!"#$%!  in the range of 
−100 to −280 J mol
–1
 K
–1
. Thus, the magnitude of ∆𝑆!"#$%!  for hematin is lower than the 
estimates for similarly sized molecules, which suggests a process leading to entropy 
increase during hematin incorporation into the growth sites on crystal surfaces. This 
process could possibly be the release of n-octanol molecules, which may be ordered at 
the crystal–solvent interface and surrounding hematin molecules in the solution. 
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3.3 Mechanism of Crystallization 
Hematin crystals that form in physiological (hemozoin) and synthetic (β-hematin) 
processes are faceted with smooth faces oriented along crystallographic planes with low 
Miller indices and high density of molecules. To elucidate the growth mechanism of 
hematin crystals, our group employed time-resolved in situ AFM to image large crystals. 
They discovered hematin crystals follow a classical mode of crystal growth, in which 
new layers are generated by 2D nucleation and spread to cover the entire facet as seen in 
Figure 36.	  	  
 
 
Figure 36: Layer growth on β-hematin [100] surfaces. (A and B) Time-resolved in situ AFM images of 
layer growth in solution at cH = 0.28 mM. (Scale bar, 250 nm.) (C) Step velocity in the [001] 
direction as a function of hematin concentration cH. 
 
3.4 Thermodynamic Properties of Crystallization 
Analyses of successive snapshots from AFM movies in our group reveal that new 
layers may either grow (I–III in Figure 37 A–D), dissolve (IV in Figure 37 A–D), or 
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retain a steady size during continuous imaging (V in Figure 37 C and D) depending on 
their radius R. They observed a reduction in the critical radius Rcrit for island growth or 
dissolution with increasing hematin concentration (Figure 37E), which is consistent with 
classical nucleation theory (CNT) applied to 2D crystal islands on a substrate. According 
to CNT, islands form as a result of fluctuations of the concentration of molecules on the 
surface.  
The dependence Rcrit (cH) is governed by the Gibbs–Thomson relation, according 
to which 
      ’     [7] 
where Ω = 0.708 nm3 is the volume of one molecule in the crystal; γ is the surface free 
energy of the layer edge; kB is the Boltzmann constant; T is temperature; cH is hematin 
concentration; and ce is hematin solubility in CBSO. The γ is estimated using the 
Turnbull empirical rule, 
,     [8] 
where Ω = 0.708 nm3 is the volume of one molecule in the crystal and ∆𝐻!"#$%!  = −37 ± 8 
kJ mol-1 as calculated from bulk solubility temperature dependence. The correspondence 
between the experimentally determined Rcrit and the a priori CNT prediction in Figure 
37E indicates that the generation of new layers on growing β-hematin surfaces is 
governed by the thermodynamics of hematin crystallization.	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Figure 37: Generation of crystal layers. (A–D) Time-resolved in situ AFM images showing growing and 
dissolving islands on a (100) face at cH = 0.25 mM. (Scale bar, 125 nm.) (E) Dependence of the 
critical radius of 2D nuclei Rcrit on ln(cH/ce). (F) Rate of 2D nucleation of new layers. 
 
3.5 Inhibition by Chloroquine 
To date, definitive evidence for antimalarial mode(s) of action remains elusive. 
Our group was able to identify the mechanism of β-hematin crystal growth inhibition by 
chloroquine. In situ AFM measurements revealed that the addition of chloroquine to 
hematin growth solutions leads to slower step growth, fewer 2D nuclei, and more rugged 
step edges (Figure 38 A-E). The impact of chloroquine at concentrations cCQ = 0–2 µM 
on layer generation and step propagation is summarized in Figure 38 F–H. There is an 
exponential decay in the rate of 2D nucleation of new layers per unit area per time, J2D, 
with increasing cCQ that is accompanied by a monotonic decrease in v (Figure 38 G and 
H). They observed a complete suppression of layer nucleation and step growth at cCQ = 2 
µM. 
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Figure 38: CQ inhibition of β-hematin growth. (A–E) Time-resolved in situ AFM images of a (100) face 
growing in solution at cH = 0.28 mM. (Scale bar, 250 nm.) (A-B) Absence of CQ. (C-E) 1 mM 
CQ. Effect of CQ on (F) rate of 2D nucleation, (G) step displacement, and (H) step velocity. 
 
3.6 Drug Solubility 
An argument that is frequently presented in the literature in favor of hematin 
crystallization in an aqueous medium is the presumed low solubility of quinoline-class 
antimalarials in organic solvent, which would seemingly reduce their efficacy as 
inhibitors of crystal growth in the lipid phase. If the solubility of drug in the organic 
solvent exceeds 1 µM, a low threshold of efficacy of chloroquine in hematin 
crystallization inhibition,134 the partitioning of drug from an aqueous phase to the organic 
phase would not limit its efficacy. 
The solubility of eight drugs listed in Figure 39 was determined. As discussed 
earlier, the general approach to malaria treatment, recommended by The World Health 
Organization,40 involves combination therapies. In this approach, two or more drugs with 
different modes of action and biochemical targets are applied simultaneously to produce a 
highly effective treatment.48 For example, an antibiotic such as doxycycline (DC), which 
causes abnormal cell division, and an antimalarial such as quinine (QN), which inhibits 
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crystallization of hematin, are administered together to eradicate the parasite from the 
body. For these reasons, six common antimalarials – amodiaquine (AQ), mefloquine 
(MQ), pyronaridine (PY), artemisinin (ART), chloroquine (CQ), and quinine (QN) – and 
two antibiotics, sulfadoxine (SX) and doxycycline (DC) were selected. The solubility of 
each drug was measured in CBSO and citric buffer to assess the difference between 
organic and aqueous solvents, respectively. 
 
 
Figure 39:	  Molecular structures of six antimalarials (AQ, QN, CQ, MQ, PY, ART) and two antibiotics (SX 
and DC) that are commonly used in malaria combination therapies. 
 
3.6.1 Extinction Coefficients 
The concentrations of antimalarials, and antibiotics were determined using UV-
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Visible spectrophotometry and the Beer-Lambert Law (Equation 1). The extinction 
coefficients of the five antimalarials, amodiaquine, quinine, chloroquine, mefloquine, and 
pyronaridine, and the two antibiotics, doxycycline and sulfadoxine, were determined in 
citric buffer and either citric buffer saturated octanol (CBSO) or water-saturated octanol 
(WSO). Tests revealed that the ε values in WSO are similar, within several percent 
deviation, to those in CBSO; hence, the ε values measured in WSO were used to 
determine the drug concentrations in CBSO. To determine ε in the respective solvent, a 
known amount of a drug was fully dissolved in a known volume of solvent. These stock 
solutions were diluted to eight concentrations and filtered through 0.22 µm 
polyethersulfone (PES) filters. Absorbance spectra in the wavelength range 200 – 800 nm 
were recorded for each concentration for each drug. A wavelength of peak absorbance 
was identified and ε at that wavelength was determined using the Beer-Lambert law as 
illustrated in Figures 40 – 42; the ε values are shown in Table 5. Each determination was 
based on two or three independent concentration series. 
The extinction coefficient of sulfadoxine in citric buffer was determined 
analogously; however, sulfadoxine powder dissolves very slowly in CBSO. To prepare 
sulfadoxine solutions in CBSO with known concentration, 2 mL of sulfadoxine was kept 
in citric buffer in contact with 2 mL of CBSO for one week. The sulfadoxine 
concentration in CBSO was calculated from the decrease of the sulfadoxine concentration 
in the citric buffer layer and the respective ε was determined as with the other drugs.   
Artemisinin does not absorb light in the UV-visible range. The concentration of 
an artemisinin stock solution was determined by keeping a known amount of the drug in 
contact with a volume of CBSO that was slowly increased over 45 days, until the entire 
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artemisinin powder dissolved. 
	  	  
Figure 40: Determination of the extinction coefficients of antimalarials AQ, QN, CQ, and MQ in water-
saturated octanol (left column) and aqueous citric buffer at pH 4.8 (right column).  	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Figure 41: Determination of the extinction coefficients of PY in CBSO (left column) and aqueous citric 
buffer at pH 4.8 (right column).  	  	  
	  	  
Figure 42: Determination of the extinction coefficients of the antibiotics DC and SX in WSO (left column, 
yellow symbols) and aqueous citric buffer at pH 4.8 (right column, purple symbols).  
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Table 5: Extinction coefficients of antimalarials in CBSO and citric buffer at pH 4.80 
 
Drug 
ε [mM-1cm-1] at λ (nm) 
CBSO or WSO Citrate(aq) 
Hematin [H] 3.1 ± 0.3               (594 nm)  
Amodiaquine [AQ] 13.2 ± 0.2             (346 nm) 17.0 ± 0.1              (340 nm) 
Chloroquine [CQ] 7.5 ± 0.2               (331 nm) 18.78 ± 0.06          (341 nm) 
Quinine [QN] 5.12 ± 0.02           (331 nm) 4.58 ± 0.02            (330 nm) 
Mefloquine [MQ] 2.712 ± 0.007       (315 nm) 3.10 ± 0.02            (315 nm) 
Pyronaridine [PY] 31.3 ± 0.8             (279 nm) 12.35 ± 0.04          (422 nm) 
Doxycycline [DC] 14.6 ± 0.2             (354 nm) 13.8 ± 0.2              (344 nm) 
Sulfadoxine [SX] 29.8 ± 0.3             (272 nm) 25.9 ± 0.1              (265 nm) 	  
 
3.6.2 Solubility Determination 
The concentration of antimalarials in CBSO and citric buffer was determined by 
UV-Visible spectrophotometry using the Beer-Lambert law (Equation 1) and the 
extinction coefficients from Table 5. To determine the solubility of antimalarial drugs in 
each solvent, solid drug powder was placed in contact with 5 mL of solvent at room 
temperature in a clean 6 mL vial. This procedure was repeated until the powder no longer 
dissolved, and the vial was then sealed with a plastic cap. A total of three vials were 
prepared for each drug-solvent combination for each temperature that was analyzed. The 
solutions were incubated at four temperatures: 5 (or 9), 25, 37, and 45°C. Every week, a 
small aliquot was removed from each vial and filtered (0.22 µm PES membrane) to 
determine the concentration using the same spectrophotometric procedure described 
above. The change in concentration was tracked as a function of time and the solubility 
was determined as the plateau across three time points. In the case of pyronaridine, its 
relatively high solubility in citric buffer enabled only one determination at 25°C due to a 
limited supply of reagent. Conversely, the low solubility of artemisinin required an 
alternative method involving the slow addition of solvent to a known mass of dry powder 
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over the course of one month, until the entire artemisinin powder dissolved. Given the 
long timeframe of the latter measurement, this procedure was only performed at a 
temperature of 25°C.	  
Drug solubility was determined spectrophotometrically by monitoring the 
evolution of soluble drug concentration over a 50-day period. A representative data set 
for chloroquine in CBSO (Figure 43A) shows that the soluble drug concentration reaches 
a plateau with prolonged time.  
 
 
Figure 43: Drug solubility in CBSO and citric buffer. 
 
The thermodynamic equilibrium and the average concentration value at the 
plateau was interpreted as solubility. The solubility for each drug at 25oC is listed in 
Figure 43B for CBSO (top plot) and citrate buffer (bottom plot). The majority of drugs 
62 
were found to have a solubility that exceeds 100 µM in both solvents, with the exception 
of pyronaridine in CBSO and artemisinin in citric buffer. When comparing the solubility 
of antimalarials, it was observed that quinine, mefloquine and artemisinin have higher 
solubility in CBSO (that exceed 10 mM). The antibiotics sulfadoxine and doxycycline 
exhibit comparable solubility in both solvents, with slightly higher values in CBSO. Note 
that even the drugs that exhibit lower solubility in CBSO than in citric buffer are soluble 
at concentrations sufficient to inhibit hematin crystallization. 
The effect of temperature on drug solubility was quantified within the range 5 – 
45°C, which encompasses the conditions selected for bulk crystallization assays in vitro 
(25°C) and the physiological environment of hemozoin formation in vivo (37°C). 
Notably, drug solubility within this temperature range does not fall below 1 µM, the 
approximate threshold concentration for effective inhibition of hematin crystal growth. 
The determinations in CBSO (Figure 43C) reveal that all tested drugs generally exhibit 
higher solubility at higher temperature. The solubility of amodiaquine exhibits a 1.5-fold 
increase. The solubility of mefloquine and quinine is nearly independent of temperature. 
For the other drugs, the solubility increases only marginally between 25 and 37°C. The 
effect of temperature on drug solubility in citric buffer (Figure 43D) reveals disparate 
effects. The solubility increases with temperature for the majority of drugs tested; 
however, the solubility of doxycycline, and to a lesser extent mefloquine, decreases with 
increased temperature. The solubility of pyronaridine at 25°C is 223.3 ±	 0.6 mM, which 
lies between that of amodiaquine and chloroquine; however, limited pyronaridine 
availability prohibited an exhaustive analysis over the full temperature range.  
Van ’t Hoff plots of the temperature dependence of solubility (Figure 43E and 4F) 
63 
yield the enthalpy ΔH and entropy ΔS of drug crystallization from the slope and intercept, 
respectively, of the linear relation between ln Ce and T-1: 𝑙𝑛𝐶! = ∆!!" − ∆!! .      [9] 
 
Equation 9 is based on the crystallization equilibrium constant Keq = Ce-1. The 
values of ΔH and ΔS for each drug extracted from data in Figure 43E and F are listed in 
the Table 6. 
Table 6: Thermodynamics of crystallization of antimalarials and antibiotics 	  
Drug 
CBSO  Citrate(aq) 
ΔH [kJ mol-1] ΔS [J mol-1K-1] ΔH [kJ mol-1] ΔS [J mol-1K-1] 
Amodiaquine [AQ] -24 ± 4   70 ± 10        -80 ± 20 290 ± 60 
Chloroquine [CQ] -25 ± 2 71 ± 7       -5.4 ± 0.8 71 ± 3 
Quinine [QN]    3 ± 2 47 ± 6         -27 ± 4 100 ± 10 
Mefloquine [MQ]   -2 ± 1 38 ± 4          21 ± 16  -70 ± 50 
Pyronaridine [PY] -56 ± 8 160 ± 30          
Doxycycline [DC] -19 ± 2 83 ± 5          47 ± 6       -160 ± 20 
Sulfadoxine [SX] -30.9 ± 0.7          105 ± 2         -26 ± 3   80 ± 10 	  
 
Collectively, the studies suggest that CBSO is a suitable biomimetic solvent for 
hematin crystallization. These pivotal pieces of information about the bulk properties of 
hematin and antimalarials in solution aid in the creation of a platform for screening and 
design of new compounds. However, a fast and easy method for calculating inhibition of 
crystallization is required.	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Chapter 4: Design of a Biomimetic Assay 
Assays play an integral role in the discovery of new pharmaceutical drugs for 
diseases.55 With high-throughput assays, companies test libraries of drugs containing 
thousands of compounds to determine their applicability. Current methods for discovery 
of new antimalarials are parasite-based assays, which do not indicate the functionality of 
the compounds whether they act by corrupting the reproductive cycle of the parasite, 
inhibiting crystallization or some other means. 
4.1 Previous Aqueous Assays 
Multiple types of aqueous assays currently exist to determine the half maximal 
inhibitory concentration (IC50) values, most of which are unseeded. The values between 
each of the assays coincide with each other. The most effective one was designed by 
Ncokazi et al.; it does not require centrifugation and reaches completion in less than two 
hours. However, seeded assays do not provide IC50 values that coincide with the 
unseeded assays, but these assays can provide knowledge for the design of a new 
biomimetic assay.  
In an assay designed by Egan and coworkers, they formed β-hematin crystals 
through a reaction of hemin to hematin by adjusting the pH from 13 to 4.5 using 1 M 
hydrochloric acid and 12.9 acetate solution.135 The reaction was allowed to proceed until 
various time intervals where the solution was analyzed with UV-visible spectroscopy by 
adding pyridine to form a complex between hematin and pyridine. Pyridine only 
complexes with non-crystalline hematin, thereby removing any residual amorphous 
material present.136 Due to this complexation, the depletion of hematin in solution over 
time can be measured to determine a rate of crystallization, which is equal to the rate of 
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depletion. This procedure can be visualized in Figure 44. Others have utilized this assay 
and adapted it to a high-throughput configuration in 96-well plates. 
 
Figure 44: Schematic drawing of unseeded assay designed by Timothy Egan’s group. The assay monitors 
the depletion of hematin in solution over time. 
 
Another assay approach was created by Chong and coworkers, where a 
supersaturated hematin solution with seed crystals in 0.1 M ammonium acetate provided 
the crystallization environment for β-hematin crystals.137 The analysis of growth was 
complicated with two separate spectrophotometry measurements: one after the addition 
of 3% SDS/0.225 M NaHCO3 to dissolve any amorphous material and the second after 
the introduction of 10 M NaOH to dissolve the crystals. The rate of crystallization was 
calculated by determining the concentration of crystalline material from the differences in 
spectroscopic measurements over time. In this assay, the induction time for 
crystallization was decreased through the use of seed crystals lowering the 
thermodynamic energy barrier. 
 
 
Figure 45: Illustration of seeded assay designed by David Sullivan’s group.  
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4.2 New Biomimetic Crystallization Assay 
A filtered solution of 0.60 mM hematin in CBSO was prepared using the method 
described below. Hematin seed crystals were added to this solution at a molar ratio of 1:4 
seeds to hematin. Portions of the seeded growth solution (ca. 0.2 mL) were extracted by 
pipette while continuously stirring and transferred to polypropylene centrifuge tubes 
containing 0.2 mL of an antimalarial drug solution to yield a final hematin concentration 
of 0.3 mM. Each centrifuge tube was shaken to ensure proper mixing and incubated in 
the dark at 22.6 ± 0.2°C. To monitor the time evolution of the concentration of 
uncrystallized hematin, three tubes were removed and analyzed every hour over a five-
hour period (for experimental statistics). First, pyridine (21.1 𝜇L, 5% v/v) was added to 
re-solubilize the hematin precipitated as amorphous solid (pyridine does not induce 
crystal dissolution within the time scale of the determination). To separate the crystals, 
each tube was centrifuged at 4000 rpm and 20°C for 10 minutes. The concentration of 
hematin in the supernatant was determined spectrophotometrically by measuring the 
absorbance at λ = 525 nm. The entire procedure is illustrated in Figure 46. For each trial, 
the rate of crystallization r (mM h-1) is determined from the slope of hematin 
concentration as a function of time. The percent inhibition of crystallization is calculated 
using the relation	  	   𝑃𝑒𝑟𝑐𝑒𝑛𝑡  𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 1− !!"!!"!#$%!!"#$%"& ×100% ,  [10] 
 
where ri is measured in the absence (i = control) and presence (i = inhibitor) of drug.  
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Figure 46: Schematic of the biomimetic assay to quantify the efficacy of potential antimalarial drugs as 
inhibitors of hematin crystallization. Benchmark studies in centrifuge tubes were adapted to a 
high-throughput configuration using multi-well plates. 
 
The above procedure was adapted to a high-throughput configuration (Figure 46) with 
only minor modification. The volume of growth solution was reduced to accommodate 
measurements in microwell plates. The concentration of filtered hematin solution in 
CBSO was increased to 0.60 mM while maintaining the same ratio of seed crystals to 
hematin. For this study, a V-bottom Corning polypropylene 96 well plate was used. A 
small volume of hematin/seed solution (ca. 100 𝜇L) was transferred by pipette into wells 
containing an equal volume of CBSO with the desired drug concentration. The plates 
were immediately shaken to ensure proper mixing and the procedure described above was 
used to determine the rate of crystallization and percent inhibition. To remove solids from 
each sample prior to UV-Vis spectroscopy measurements, the plate was centrifuged at 
3,000 rpm and 20°C for 10 minutes, then 100 𝜇L of the supernatant in each well were 
transferred to a flat bottom Corning polypropylene 96 well plate. The absorbance at λ = 
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525 nm was measured for all samples using a Tecan Infinite200 Pro microplate reader (an 
entire 96-well plate requires 1.5 minutes of scanning time). 
4.3 Seed Crystal Preparation 
All glassware was thoroughly cleaned with 0.1 M NaOH to remove residual 
hematin. The glass containers were then washed with soap and rinsed with DI water and 
acetone.  
 
Figure 47: Process of manufacturing β-hematin seed crystals for biomimetic assay. 
 
To prepare β-hematin seed crystals, a 7.7 mM hemin solution was first prepared 
by dissolving hemin in 0.1 M NaOH in a sealed glass container that was heated at 60°C 
in a water bath under continuous stirring at 150 rpm.138 Within 10 min, the solution was 
neutralized using 1.0 M HCl; it was found that exposing hemin to NaOH for more than 
20 minutes resulted in an amorphous product. A 12.9 M acetate buffer at pH 4.5 was 
prepared by mixing sodium acetate trihydrate and glacial acetic acid, which was then 
stored at 60°C for an hour and subsequently incubated at	  70°C for 22 hours. This buffer 
was added to the hematin solution at 1:1 ratio. The mixture was placed in a freezer at -
18°C for 15 minutes, and the formed residue was filtered through a 0.20 µm Nylon filter 
and rinsed sequentially with 100 mL DI water, 100 mL of a 0.225 M NaHCO3 solution 
containing 0.105 M SDS, and 100 mL DI water. The filter cake was placed in a glass 
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Petri dish over a layer of Drierite and dried for 48 hours in an incubator at 37°C. It was 
then removed and crushed into a fine powder using a mortar and pestle. This powder was 
stored for a maximum of three weeks in a sealed vial in the dark. This procedure can be 
visualized in Figure 47. 
4.4 Seed Crystal Characterization 
Powder X-ray diffraction (XRD) patterns of seed crystals were collected on a 
Siemens D5000 X-ray diffractometer with CuKα radiation (40 kV, 40 mA, λ = 1.54 Å). 
Crystal size and morphology were analyzed by scanning electron microscopy (SEM) 
using a FEI XL-30FEG microscope. Seed samples for microscopy imaging were mounted 
on metal specimen stands using adhesive carbon tape (Ted Pella Inc.) and coated with ca. 
25 nm carbon using an AJA UHV six-source sputtering device. 
4.5 Preparation of Hematin and Antimalarial Solutions 
Hematin solutions for crystal growth experiments were prepared by placing 20 
mL CBSO and an amount of hematin powder sufficient for a 6 mM solution in a 20 mL 
glass vial. The unsealed vial was kept at 100°C in the absence of direct light. Solution 
samples were periodically extracted from the solution by pipette. Each aliquot was 
filtered through a 0.2 µm polyvinylidene fluoride (PVDF) membrane, and the hematin 
concentration was measured spectrophotometrically using a Beckman Coulter DU 800 
Spectrophotometer with Tungsten and D2 lamps. 
Solutions of antimalarials or antibiotics were prepared by placing solid drug 
powder in contact with 20 mL of CBSO in a clean glass vial sealed with a plastic cap. 
The solutions were incubated in the dark at 22.6 ± 0.2°C, and then were filtered with a 
0.2 µm PVDF membrane. The exact drug concentration was determined 
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spectrophotometrically using extinction coefficients determined from data in Figures 40 – 
42. When necessary, the concentration was adjusted by dilution with CBSO. 
4.6 Screening Drug Efficacy as Hematin Crystallization Inhibitors 
The most significant feature of the proposed assay is the use of CBSO as a 
solvent. To monitor the extent of hematin crystallization in CBSO, crystalline hematin 
was quantified as the difference between initial hematin in the solution and the amount 
present during crystallization, as in previous studies.135,137 A problem encountered in this 
approach is the presence of amorphous hematin, which sequesters a fraction of hematin in 
a third phase and lowers the measurement of the concentration of uncrystallized hematin. 
To address this issue, Egan and coworkers136 proposed the addition of pyridine prior to 
concentration determination. Pyridine forms a relatively strong complex with hematin 
and dissolves potential amorphous residue.136 In the presence of excess pyridine, all non-
crystalline hematin is complexed with pyridine. The amount of hematin-pyridine 
complex is used as a measure of uncrystallized hematin in solution when determining the 
rate of hematin crystal growth. The UV-Vis spectra in Figure 48A reveal a significant 
shift in the hematin absorbance peaks due to the addition of pyridine. These shifts 
indicate complexation between hematin and pyridine. The isosbestic point at 513 nm 
(constant absorbance at varying pyridine concentration) suggests the formation of a 1:1 
hematin:pyridine complex. At pyridine concentration above 5.4% v/v, the spectra do not 
change in response to additional pyridine, indicating complete hematin complexation. 
Hence, pyridine concentration at 5 % v/v was chosen as optimal for the assay.   
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Figure 48: (A) UV-Vis absorbance spectra of hematin in CBSO at pyridine concentrations from 0 to 9% 
v/v. (B) Determination of the extinction coefficient ε of the hematin-pyridine complex at 5% 
v/v pyridine in CBSO solution at a wavelength λ = 525 nm.  
 
To quantify the amount of hematin held in a pyridine complex in the presence of 
5% v/v, the extinction coefficient of the hematin:pyridine complex was determined. The 
data on the absorbance at the top of the peak at 525 nm in Figure 48B yield ε = 3.76 ± 
0.07 mM−1cm−1. In the high-throughput version of the assay implemented in 96 well 
plates, this value of ε was used to determine the optical path length in the wells. Solutions 
of eight distinct hematin concentrations containing 5% v/v pyridine were loaded into 
eight wells of the 96-well plate. The absorbance of each well was measured using a 
Tecan Infinite200 Pro microplate reader. The polypropylene plate bottom contributes a 
constant A0 to the total absorbance leading to a non-zero intercept in the Beer-Lambert 
law,  
A = A0 + εbc.      [11] 
A linear fit of this relation to the data in Figure 49 yields the optical path b = 0.193 cm 
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and A0 = 0.130 ± 0.004. 
	  
Figure 49: Characterization of the optical absorbance at wavelength λ = 525 nm of hematin in the presence 
5% v/v pyridine in CBSO held in a polypropylene 96-well plate.  
 
Seed crystals (Figure 50A) were employed to bypass nucleation and reduce the 
time of crystallization for more efficient screening of inhibitors, similar to Chong and 
coworkers.137 Since β-hematin crystal surfaces oxidize in contact with air, seeds should 
not be stored for long periods of time. Each batch of seeds was analyzed by powder X- 
ray diffraction (XRD) to test their crystallinity. It was found that published protocols for 
seed synthesis can yield either crystalline or amorphous product (Figure 50B). The lack 
of crystallinity may lead to irreproducible crystallization kinetics. For example, a hematin 
crystallization assay was performed using three different approaches: (i) absence of 
seeds, (ii) use of amorphous seeds, and (iii) use of crystalline seeds. The data in Figure 
50C demonstrate that there is a marked difference in the induction period and 
crystallization rates between the three approaches. In the absence of seeds, there is a short 
induction period (ca. 1 day) followed by a rate of growth much slower compared to the 
crystalline seeded growth assays. The addition of either amorphous or crystalline seeds 
eliminates the induction period and leads to more rapid depletion of solute. The use of 
amorphous seeds can falsely give the appearance of crystallization where the apparent 
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rate of growth (i.e., slope of curves in Figure 50C) lies between the values of non-seeded 
and crystalline seed assays. In these studies, it could not be determined whether the 
reduction in free hematin concentration was associated with heterogeneous nucleation 
and growth of new crystals or condensation of amorphous solid (i.e., the mass of products 
was insufficient for XRD analysis). This observation underscores the importance of 
verifying the crystallinity of seed batches. 
 
 
Figure 50: (A) Scanning electron micrograph of hematin crystal seeds. (B) Powder XRD patterns of 
amorphous hematin and crystalline β-hematin. (C) Evolution of the concentration of soluble 
hematin in the absence of seeds and in the presence of amorphous and crystalline seeds.  
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An important aspect of the proposed procedure is that hematin crystallization in 
the presence or absence of inhibitors can be assessed in a relatively short period of time 
(≤ 5 hours), which is practical for drug screening assays. Within the first five hours of 
crystallization the growth rate is approximately linear. Variations from one seed batch to 
another lead to disparities in the measured rate of crystallization. To account for this 
experimental uncertainty, the effect of antimalarials on hematin crystallization is reported 
using the percent inhibition, defined in Equation 10 as the ratio of growth rate in the 
presence of inhibitor relative to that of the control in the absence of drug. Using this 
relative change in growth rate minimizes variability between different seed batches. An 
example of hematin growth in the presence of the antibiotic doxycycline is provided in 
Figure 51. Figure 52 shows the change in spectra correlating to the data in Figure 51. The 
rate of crystal growth, measured as the slope of the linear correlation (solid lines), 
decreases monotonically with increasing drug concentration. From these plots, drug 
potency and its efficacy are extracted for inhibiting the growth of hematin crystals. 
 
 
Figure 51: The evolution of free hematin concentration CH over five hours in the presence of varying 
concentration of doxycycline (DC).  
 
75 
 
Figure 52: UV-Vis spectra from a bulk crystallization assay indicating a decrease in the concentration of 
free hematin for measurements in (A) the absence of inhibitor (control) and (B) in the presence 
of 0.108 mM doxycycline (DC). These spectra correlate to the data presented in Figure 51.  
 
In Figure 53A, the percent inhibition of hematin crystallization is reported as a 
function of inhibitor concentration for four quinoline-class antimalarials: amodiaquine, 
quinine, chloroquine, and mefloquine. As shown in Figure 39, each drug is comprised of 
different functional moieties, but they share a common quinoline base. With the 
exception of mefloquine, all of the tested antimalarials are capable of inhibiting growth 
by more than 80%. The findings reveal that 0.1 mM concentration of amodiaquine is 
sufficient to nearly suppress hematin crystallization. Few studies in literature report 
growth inhibitors capable of reaching such high efficacy in bulk crystallization assays 
without leading to the promotion of polymorphs or the precipitation of amorphous 
product. Reported values of percent inhibition for a wide range of crystalline materials 
tend to be around 60%,139 which is the approximate value observed for hematin growth in 
the presence of mefloquine. The other two antimalarials tested here (chloroquine and 
quinine) inhibit growth in the range 60 – 90%, which is similar to highly effective 
inhibitors reported in prior studies of inorganic crystals.140-143 The general trends in 
Figure 53A are consistent with a Langmuir-like behavior wherein the coverage of 
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inhibitor on hematin crystal surfaces reaches a maximum (corresponding to the plateau in 
percent inhibition) beyond which any further addition of inhibitor has no appreciable 
effect on crystal growth.  
 
 
Figure 53: Percent inhibition of hematin crystallization. (A) The effect of four antimalarials: amodiaquine 
(AQ), chloroquine (CQ), quinine (QN), and mefloquine (MQ). (B) The effect of artemisinin 
(ART) and two antibiotics: sulfadoxine (SX) and doxycycline (DC).  
 
The effect of one additional antimalarial, artemisinin, along with two antibiotics, 
doxycycline and sulfadoxine, was determined. The solubility of pyronaridine in CBSO 
(Figure 43) was not sufficient to generate a full inhibition curve. As shown in Figure 
53B, quantification of hematin crystallization in the presence of artemisinin reveals no 
apparent change in growth rate with drug concentration, which is not surprising 
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considering prior studies suggest that an activated form of artemisinin (with the 
endoperoxide bridge cleaved) is the effective suppressor of malaria parasites.100,144 
Conversely, doxycycline was found to be a weak inhibitor of hematin crystallization that 
is capable of achieving comparable percent inhibition as the antimalarials in Figure 53A, 
but at much higher drug concentration. Unexpectedly, measurements of sulfadoxine 
revealed promotion of hematin crystal growth (observed as negative percent inhibition) at 
low drug concentration (< 0.06 mM), and no appreciable influence on crystal growth at 
higher concentrations. Presently, there are three proposed mechanisms for modifier 
promotion of crystal growth: (i) solute-promoter interactions increase the local 
supersaturation at crystal interfaces due to an enhanced attraction of solute molecules to 
the surface,145 (ii) reduction of the energy barrier(s) for solute attachment by disruption of 
the solvation layers at the crystal surface as a result of promoter-crystal interactions,146-148 
and (iii) adsorbed promoters decrease the energy of advancing layers at step edges on the 
crystal surface.149 Drawing upon examples from literature for other types of crystalline 
systems, it is reported for calcite (CaCO3) crystallization that certain molecules act as a 
growth promoter at low concentration and switch to a growth inhibitor at higher 
concentration.146,150 Prior studies seem to indicate that the promotion-to-inhibition 
transition occurs when the adsorbate coverage on crystal surfaces is sufficient to induce 
step pinning. In other examples, such as calcium oxalate monohydrate crystallization, 
molecules have been observed to act strictly as a promoters, irrespective of their 
concentration.140 In this study of hematin crystallization, the exact mode of action 
governing sulfadoxine promotion of growth is not well understood. 
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Table 7: Comparison of antimalarial and antibiotic IC50 values. 
Compound 
IC50  values 
Assay 
CQ-susceptible 
parasites (strain)a 
CQ-sensitive 
parasites (strain)a 
Amodiaquine 
[AQ] 
16 µM 7.8 nM (3D7)151  
8.5 nM (HB3)151  
3.0 nM (NF54)152  
10.1 nM (NF54)153  
9.3 nM (wild)154  
Chloroquine 
[CQ] 
25 µM 14.0 nM (3D7)151  
18.5 nM (HB3)151  
13.0 nM (NF54)155  
10.0 nM (NF54)152  
12.9 nM (NF54)153  
25 nM (3D7)156  
41 nM (HB3)156  
29.0 nM (KH-
266)157  
76 nM (wild)154  
Quinine [QN] 32 µM 34.2 nM (3D7)151  
36.8 nM (HB3)151  
22.0 nM (NF54)158  
132.0 nM (NF54)153  
134 nM (3D7)156  
109 nM (HB3)156  
178 nM (L3)159  
90.1 nM (KH-
266)157  
150 nM (wild)154  
Mefloquine 
[MQ] 
71 µM 43.9 nM (NF54)153  
51 nM (3D7)156  
36 nM (HB3)156  
11.4 nM (L3)159  
67.7 nM (KH-
266)157  
Pyronaridine 
[PY]160 
-------- 1.9 nM (NF54)153  
24 nM (3D7)156  
16 nM (HB3)156  
 
Doxycycline 
[DC] 
110 µM 10.8 µM (3D7)156  
12.1 µM (HB3)156  
11.3 µM (wild)154  
Sulfadoxine 
[SX] 
No 
inhibition 
--------- 23.7 µM (wild)161  
a NF54 = African origin Plasmodium falciparum strain; 3D7 = 
parasite line cloned from NF54; HB3 = Plasmodium falciparum 
strain from Honduras; L3 = strain of Plasmodium falciparum from 
Ivory Coast; wild = strain from Gabon; KH-266 = Southeast Asia 
origin Plasmodium falciparum strain 
 
When comparing the relative effect of antimalarial drugs at 50% inhibition of 
hematin growth, the following order of inhibitor potency (from lowest to highest drug 
concentration) was observed: amodiaquine > chloroquine > quinine > mefloquine >> 
doxycycline >> sulfadoxine. Interestingly, this trend is almost identical to the IC50 values 
of each drug reported in literature for parasite models using a variety of Plasmodium 
strains (see Table 7). The IC50 value refers to the inhibitory concentration (IC) of drug 
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where the response (i.e., parasite population) is reduced by half. Prior studies reveal the 
following order of drug potency (from lowest to highest IC50): amodiaquine > 
chloroquine > mefloquine > quinine >> doxycycline >> sulfadoxine. Comparison of our 
assay with parasite models shows excellent agreement, with the exception of one outlier: 
the relative potency of mefloquine and quinine in our assay does not match the parasite 
model. Caution should be taken when directly comparing the results of in vitro and in 
vivo studies. Nevertheless, the similarity in IC50 trends suggests that the bulk 
crystallization assay is an effective tool for identifying lead drug candidates and 
comparing relative efficacy.  
4.7 High-throughput Assay 
The commercial relevance of drug-screening assays relies on their ability to 
identify lead candidates in a rapid timeframe. As a proof of concept, the biomimetic assay 
developed above was adapted to high-throughput screening of numerous prospective 
drugs in parallel. Instead of centrifuge tubes, 96-well plates were employed. In this high-
throughput configuration, the solution volume in individual runs was reduced from 400 
µL (centrifuge tubes) to 200 µL (plate wells). The modified platform was tested using the 
conditions described above.  
In the multi-well plates, hematin crystallizes at a much slower rate than in the 
centrifuge tubes. Slower rates of crystal growth impede the quantification of the percent 
inhibition of hematin crystallization as the differences between hematin growth in the 
absence and in the presence of inhibitor are commensurate with the error of UV-Vis 
measurements; and this similarity increases the likelihood of identifying false positives 
during inhibitor screening. To address this problem, the starting hematin concentration 
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CH was adjusted to increase the supersaturation, which alters the rate of crystallization. 
As shown in Figure 54A, the growth rate increases monotonically as a function of CH. 
The data in Figure 54 illustrate the good reproducibility of the assay in multi-well plates, 
i.e., growth rates obtained using two separate crystal seed batches, each in duplicate, 
agree. For all measurements reported herein, a hematin concentration of 0.60 mM was 
used that induces growth at a rate observed for the 0.3 mM concentration in the 
centrifuge tubes.  
 
 
Figure 54: (A) Effect of starting hematin concentration CH on the rate of growth using a 96-well-plate 
configuration. (B) Percent inhibition of hematin crystallization as a function of quinine 
concentration, CQN, in biomimetic assays employing centrifuge tubes and a 96-well plate.  
 
In Figure 54B, the percent inhibition of hematin measured in the multi-well plate 
and centrifuge tubes was compared, selecting quinine as a representative growth 
inhibitor. The general trend of the two curves is similar, which confirms that the high-
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throughput configuration can be used to screen inhibitors of hematin crystallization. For 
reasons that are not entirely clear, the percent inhibition measured in the multi-well plate 
is slightly higher. Potential reasons for this observation may be attributed to the fact that 
multi-well plates have smaller volume (which may slow down buoyancy-driven 
convection), the plates are made of different polymeric material (which may potentially 
alter crystal and/or inhibitor adsorption on container walls), and the multi-well plate 
requires higher supersaturation. Despite these small differences, this proof-of-concept 
study indicates that the biomimetic assay proposed here has the potential to be applied as 
a screening platform for hematin crystallization in order to identify and characterize new 
generations of antimalarial drugs. 
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Chapter 5: Conclusions of Hematin Project 
In summary, hematin solubility and crystallization was examined in media that 
mimic aqueous and lipid regions of the parasite DV. The formation of hemozoin in vivo 
is not well understood—notably the regions within the vacuole where hematin nucleates 
and crystallizes. These studies reveal that hematin solubility in an aqueous solution at pH 
4.8 is nearly four orders of magnitude lower than that in an organic solvent (water-
saturated octanol) that mimics the environment in the lipid nanospheres within the DV. 
The effects of antimalarial and antibiotic drugs on bulk hematin crystallization 
were assessed in a biomimetic growth medium. Systematic analysis of drug-solvent 
thermodynamics confirmed that all drugs are sufficiently soluble in CBSO, resulting in 
concentrations that are high enough to inhibit hematin crystals. Although these studies do 
not conclusively identify the exact regions within the parasite digestive vacuole where 
hematin crystals are formed, the collective mesoscopic and microscopic investigations 
reported here strongly suggest that the organic lipid environment mediates hemozoin 
formation. 
Bulk crystallization in CBSO employing hematin crystal seeds was shown as an 
effective method of quantifying inhibitor efficacy. Moreover, comparison of seeded 
growth assays for various drugs revealed their relative potency. Here, several advantages 
of the biomimetic bulk crystallization assay over current parasite models was reported. 
For instance, seeded growth in CBSO requires relatively short time (ca. ≤ 5 hours) to 
assess the efficacy of growth inhibitors. Crystallization-based assays also provide more 
information regarding the mechanism of drug action. Notably, crystalline product from 
drug screening assays can be analyzed by more rigorous techniques, such as electron or 
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scanning probe microscopy, to examine the effects of inhibitors on crystal size, habit, and 
surface topography from the macroscopic to near molecular length scale. Identifying 
effective crystal growth inhibitors can also help develop structure-performance 
relationships wherein the properties of the drug (i.e., molecule structure and 
functionality) could potentially serve as heuristic guidelines to design molecular 
analogues for additional testing, thereby reducing the number of compounds that need to 
be screened prior to identifying a lead candidate(s).  
A high-throughput configuration was described that is potentially viable for 
conducting bulk crystallization in parallel, thus offering an efficient method of screening 
antimalarial drug compounds. One aspect of this approach that is lacking is the ability to 
discern the bioavailability of these compounds. To this end, in vivo tests are essential, and 
could be combined with bulk crystallization assays wherein the latter would serve as a 
pre-screening stage to collect useful information on drug-crystal interactions for the 
design of new compound libraries, and improve the overall efficiency of drug screening. 
 
. 
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Chapter 6: Gallstones & Atherosclerosis 
The presence of gallstones dates back centuries with multiple gallstones found in 
a mummified Egyptian priestess.162 However, the disease was first described by a 
Florentine pathologist, Antonio Benivenius, in 1507 posthumously.163 Not only were 
gallstones found in mummified Egyptians, atherosclerotic lesions were found in pharaoh 
mummies from more than 3500 years ago.164 Hippocrates described the sudden cardiac 
death of humans during his lifetime as a physician. At approximately 300 B.C., 
Erasistratus documented the symptoms of peripheral arterial disease by the intermittent 
cramping in the leg, or claudication. From the 1550s to 1800s, several famous physicians, 
including Gabriele Falloppio and Caleb Hillier Parry, observed pathological findings in 
arteries in various regions of the body and suggested the presence of calcified 
atherosclerotic lesions. In 1835, Jean Lobstein coined the term arteriosclerosis. 
Both of these diseases have been present for centuries afflicting hundreds of 
thousands of individuals.165 During this time, knowledge has been accumulated regarding 
various treatment methods, likelihood of incidence, risk factors, and the pathology. 
6.1 Gallstones 
Gallstone disease, or cholelithiasis, is one of the most common and most 
expensive to treat of digestive disorders that require admission to hospital. In Europe and 
the United States, gallstones are found in 15-20% of the adult population, but 40-60% of 
these people are asymptomatic.166 Each year in the United States, more than one million 
people are newly diagnosed with gallstones. The direct costs of diagnosis and treatment 
are more than $5 billion annually.  
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6.1.1 Types of Gallstones 
In humans, three types of gallstones can occur: cholesterol stones, black pigment 
stones and brown pigment stones.56 Approximately 75% of gallstones are cholesterol 
based with black pigment stones accounting for 20% and brown pigment stones are found 
in 5% or less.167 A variety of human gallstones can be seen in Figure 55.168 
 
Figure 55: Variety of human cholesterol gallbladder stones with different shapes, sizes and compositions 
of cholesterol.168 
 
Cholesterol and black pigment stones develop only in the gallbladder in a 
bacterially sterile environment.56 In contrast, brown pigment stones form due to a chronic 
anaerobic bacterial infection of bile, which usually occurs in the extrahepatic bile ducts 
and intrahepatic bile ducts. Rarely do brown pigment stones occur in the gallbladder and 
only after an inflammation of the gallbladder, or cholecystitis. The presence of brown 
pigment stones is principally in underdeveloped countries. 
6.1.1.1 Black or Brown Pigment Stones 
The pathogenesis of black pigment stones results from shifts in the lipid and 
lipopigment compositions of bile stored in the gallbladder. Black and brown pigment 
stones consist of calcium salts of bilirubin, shown in Figure 56.169 Bilirubin is a yellow 
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breakdown product of normal heme catabolism. This is the compound responsible for the 
yellow color of bruises.  
 
Figure 56: Molecular structure of bilirubin in black and brown pigment stones. 
Bilirubin constructs polymers with large amounts of mucin glycoproteins in black 
pigment stones.170 Black pigment stones are common in individuals who have underlying 
conditions causing their body to produce excess bilirubin, such as cirrhosis (liver does not 
function properly) or chronic hemolytic conditions (thalassemias or sickle cell anemia). 
Meanwhile, brown pigment stones are composed of calcium salts of unconjugated 
bilirubin with varying amounts of protein and cholesterol. In the primary bile ducts, 
stones that originate there are usually associated with a bacterial infection resulting in 
brown pigment stones. The bacteria in the biliary system release β-glucuronidases.56 
These hydrolyze glucuronic acid from conjugated bilirubin resulting in unconjugated 
bilirubin. The unconjugated bilirubin precipitates in the form of calcium salts.  
6.1.1.2 Cholesterol Stones 
Cholesterol stones are composed of more than 80% cholesterol as seen in Figure 
57. They often contain alternating layers of cholesterol crystals and mucin glycoproteins. 
Some calcium salts and bile pigments can also be included in the stone. The addition of 
the proteins improves the strength of cholesterol stones are pure cholesterol crystals are 
soft.56 
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Figure 57: Chemical structure of cholesterol. 
For cholesterol crystals to form, the cholesterol concentration in bile exceeds the 
solubility in solution.171 It then precipitates out as crystals, producing stones. Cholesterol 
is only slightly soluble in aqueous media (~10-8 M).76 However, bile also contains mixed 
micelles of bile salts and phospholipids, mostly phosphatidylcholine.4,171,172 The 
concentrations of the bile salts and phospholipids control the degree of cholesterol 
saturation as illustrated in Figure 58.168  
 
Figure 58: Ternary phase diagram of cholesterol, phospholipids and bile salts illustrating how cholesterol 
solubility is dependent upon the concentration of phospholipids and bile salts.168 
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Cholesterol is solubilized into vesicles in supersaturated bile by phospholipids.173 
From these vesicles, monohydrate crystals can precipitate becoming entrapped in 
gallbladder mucin gel with bilirubinate.174 These will agglomerate into a gallstone as 
shown in Figure 59.175 Cholesterol is most soluble when the lipid concentration contains 
more than 50% bile salts with smaller concentrations of phospholipids. Overall, the 
greater degree of cholesterol supersaturation, the higher the risk for gallstones which 
correlates to solubility as the driving force of crystallization. The solubility of cholesterol 
in human gallbladder bile ranges from 5-50 mM.176 
 
 
Figure 59: SEM images of cholesterol monohydrate crystals aggregated in gallstones.175  
6.1.2 Signs & Symptoms 
Approximately half of people with gallstones are asymptomatic. However, if the 
flow of bile is slowed or blocked, a number of problems can occur. When a gallstone 
causes blockage of the cystic duct, there are severe episodes of pain (biliary colic).177 
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During this, the gallbladder contracts vigorously against the blockage resulting in 
spasmodic severe pain. The pain occurs in the upper right portion of the abdomen, center 
of the abdomen just below your breastbone, back pain between the shoulder blades and/or 
pain in the right shoulder. These episodes usually last only an hour or two and occur 
infrequently. Other symptoms include jaundice (yellowing of the skin and the white part 
of the eyes), dark urine, light-colored bowel movements, fever and chills.  
One effect of gallstones is an inflamed gallbladder, or cholecystitis. There are 
other causes of inflammation such as excessive alcohol use, infections or tumors, but the 
most common culprit is gallstones. The body reacts by swelling and pain of the 
gallbladder walls. This inflammation can last for several hours or up to a few days with 
possible fever.178 At this time, the gallbladder is susceptible to infection by intestinal 
bacteria, which occurs about 20% of the time. Occasionally, the gallbladder will rupture, 
resulting in a surgical emergency. 
If the gallbladder experiences gallstones or inflammation often, it can become 
rigid and scarred causing a dysfunctional gallbladder or chronic gallbladder disease. For 
this, the symptoms are more vague but constant. The person experiences abdominal 
fullness, indigestion, increased gas and chronic diaherra.  
6.1.3 Diagnosis & Detection 
To diagnose whether gallstones are present, doctors will most commonly 
recommend an abdominal ultrasound or computerized tomography (CT) scan.179 With 
images from these instruments, the doctor can analyze them for the presence of 
gallstones. These tests are safe, non-invasive, widely available and are low cost 
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procedures. Blood tests can also reveal abnormalities associated with gallstones, such as 
infection, jaundice, pancreatitis or other complications.  
Other methods will use special dyes to highlight the regions of the bile ducts and 
ascertain whether a gallstone is causing a blockage; tests include hepatobiliary 
iminodiacetic acid (HIDA) scan,180 magnetic resonance imaging (MRI) or endoscopic 
retrograde cholangiopancreatography (ERCP).181 During an ERCP, the gallstone can be 
removed if found.  
In this procedure, an endoscope with a small camera mounted on the end is 
inserted down the esophagus. Air is pumped into the stomach and duodenum making it 
easier to see. The bile and pancreatic ducts are located where they empty into the 
duodenum. A catheter is inserted through the endoscope and into the ducts where a 
special dye is injected, making the ducts more visible for the x-ray imaging. The doctor 
can break up or remove stones present or a variety of other procedures depending on the 
affliction.  
6.1.4 Treatment Methods 
Prior to the late 1800s, treatment for gallstones was cholecystostomy. In this 
treatment, doctors would perform surgery where they would open the body and 
gallbladder to remove the stones and drain the fluid. At the time, they feared removing 
the gallbladder entirely from the body would kill the patient. However, this procedure 
only provided temporary relief as fistulas formed and continued pain ensued.182 
German physician Carl Johann August Langenbuch became frustrated with his 
patients suffering after these gallbladder procedures and aimed to find a cure. In 1882, 
Langenbuch performed an open cholecystectomy, surgical removal of the gallbladder, on 
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a man who had ached with gallstones for 16 years.183 Overnight, he cured the man’s 
painful condition providing a solution which would not only not kill patients, but provide 
a painless future. Open cholecystectomies became the gold standard for gallstone 
treatment for almost a full century. 
During this time, other methods of treatment were developed for those patients 
who could not undergo surgery. In 1937, a report of complete dissolution of gallstones by 
bile acids was published.62 In the 1970s, bile acid chenodeoxycholic acid emerged as an 
oral drug for removing gallstones.65 In the 1980s, another bile salt ursodeoxycholic acid 
was introduced as another prescribed drug to cause dissolution of gallstones.66 Both bile 
acids are shown in Figure 60. In this method, chenodeoxycholic acid increases the 
solubility of cholesterol in bile, causing dissolution. For ursodeoxycholic acid, it reduces 
the synthesis of cholesterol in the liver and its secretion into the bile. For this method to 
be applicable for a patient, the gallstones must be composed of cholesterol (pigment 
stones would be unaffected) and the size of the stones must be less than 1.5 cm. Only 
20% of all patients who undergo cholecystectomies meet these requirements.184 In bile 
acid therapy, the efficacy is dependent upon the size and content of the stones as well as 
patient compliance. Bile acids must be taken daily for up to two years. This particular 
method has not become popular in the United States, due to its limited efficacy, 
inconvenience and improvement of other methods. 
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Figure 60: Structures of two bile acids used in oral dissolution therapy for gallstones. 
There are other dissolution therapies in clinical investigations. One method in 
particular uses a percutaneous catheter placed through the liver introducing solvents into 
the gallbladder to dissolve cholesterol gallstones.185 A nasobiliary catheter can be utilized 
as well.186 Methyl tert-butyl ether is main solvent tested with repeated instillations and 
drainage to dissolve the stones in 24 hours. A side effect is mild acute inflammation in 
the gallbladder mucosa and it must be monitored to prevent seepage into the duodenum, 
where it causes severe mucosal irritation. An alternative less toxic solvent being tested is 
n-propyl acetate. However, this method has a similar problem with recurrence of stones 
after treatment.187 
In 1986 in Munich, the first use of extracorporeal shockwave lithotripsy plus oral 
bile acids was performed.63 In this therapy, acoustic shockwaves, generated by spark-gap, 
electromagnetic or piezoelectric technology, are sent through the body to break stones 
into small pieces. The additional bile acid dissolution therapy should help dissolve or 
pass the stones into the small intestine. The main downside to both the bile acids therapy 
or shockwave lithotripsy is the recurrence of stones in 30-50% of the cases five years 
afterward.188,189  
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The major revolution for gallstone treatment came in 1985 and 1987 when 
laproscopic cholecystectomies were performed by Erich Mühe and Philippe Mouret, 
respectively.190 In this procedure, a small incision is made where a laparoscope, thin 
lighted tube with a camera, is inserted and several other small incisions are made where 
surgical instruments are inserted. After the two and a half hour procedure, patients were 
ready to leave the hospital later that day.191 With the laparoscopic cholecystectomy, the 
rectus abdominus muscle is not cut during an incision like in an open cholecystectomy 
decreasing the recovery time by a month. In Figure 61, the algorithm for treatment based 
on the patient results in most individuals receiving a laparoscopic cholecystectomy.168 
Every year, about 700,000 individuals have cholecystectomies.  
 
Figure 61: Algorithm for treatment of gallstones based on symptoms and conditions of patient.168 
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6.1.5 Risk of Gallstones  
Certain features can increase a person’s risk factor: age, female gender, oral 
contraceptive use, rapid weight loss, pregnancy (having given birth), obesity, type 2 
diabetes, dyslipidaemia (hypertriglyceridacemia and low HDL serum cholesterol), 
hyperinsulinaemia, and sedentary life-style.192-197 Specific ethnic groups are also more 
prone to gallstones including specific Indian tribes from around the world. In the United 
States, gallstones have a low presence in African Americans and higher prevalence in 
Mexican Americans. 
6.2 Atherosclerosis 
In the United States, cardiovascular, lung and blood diseases attribute for a large 
morbidity, mortality and economic burden on individuals and families. In 2010, these 
diseases accounted for over 1 million deaths, approximately 41 percent of all deaths in 
the United States.198 The economic costs of illness, injuries and death from these diseases 
in 2009 were $424 billion, accounting for 23 percent of medical costs. Of all diseases, 
cardiovascular is the leading cause of death, representing 32 percent of all deaths. 
Atherosclerosis is one of the most common forms. Most of our knowledge of this disease 
comes for the last century. 
6.2.1 Formation of Plaque 
In atherosclerosis, or arteriosclerotic vascular disease, an artery wall thickens as a 
result of build-up of fatty materials or plaque. To begin, atherosclerosis develops from 
low-density lipoproteins (LDL), as shown is Figure 62.199 LDL is a globular shaped 
molecule with a hollow core used to transport cholesterol throughout the body. The 
cholesterol is used to generate brain tissues, vitamin D, etc. Cholesterol can only move in 
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the bloodstream by transportation by LDL due to its low solubility in water, which 
constitutes 70% of blood. 
 
Figure 62: Schematic of high-density lipoprotein (HDL) and low-density lipoprotein (LDL). Apo refers to 
apolipoprotein.199 
 
LDL molecules become oxidized by free radicals, mostly oxygen free radicals. 
When oxidized LDL contacts an artery wall, it damages the endothelial cells triggering a 
series of reactions to repair the damage. The immune system sends white blood cells, 
specifically macrophages and T-lymphocytes, to absorb the oxidized LDL, forming 
specialized foam cells.200 High-density lipoproteins (HDL), seen in Figure 62, are 
recruited by the foam cells to remove the fats (cholesterol).199 However, if the white 
blood cells are unable to process oxidized LDL or HDL levels are insufficient, rupture 
ensues. This rupture deposits cholesterol into the artery wall, triggering more white blood 
cells. Thus, the cycle repeats.201 
Eventually, inflammation of the artery occurs. The muscle cells enlarge and create 
a hard cover over the affected area due to the cholesterol plaque. The hard cover 
produced reduces blood flow and increases blood pressure as this narrows the artery in 
question.202  
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In the atheromatous plaque formed in the arteries, there are three components. 
The first component is the soft, flaky, yellowish material at the center of large plaques, 
composed of macrophages called the atheroma. Underlying areas of cholesterol crystals 
comprise the second component. The last section is the calcification at the outer base of 
more developed lesions. 
The progression of atherosclerosis is slow and cumulative over decades and 
complications arise suddenly. Commonly, a soft plaque will suddenly rupture creating a 
thrombus, a blood clot in a vessel which remains there.203,204 The blood flow will rapidly 
slow or completely cease due to the thrombus, resulting in the death of the tissues fed by 
the artery in question in five minutes. This is known as an infarction. Infarctions specific 
to coronary arteries are referred to as heart attacks, and strokes are infarctions in arteries 
in the brain. 
6.2.2 Symptoms 
The atherosclerosis process usually begins in adolescence and is found in most 
arteries. However, it is mostly asymptomatic and left undetected by most diagnostic 
methods during life.205 The first sign of atherosclerosis for about 65% of men and 47% of 
women is heart attack or sudden cardiac death. Depending on the location of the 
blockage, other symptoms could persist.206 Other symptoms could be stroke, chest pain, 
leg pain, leg cramps, erectile dysfunction, shortness of breath, arrhythmias (irregular 
heartbeats), sudden numbness, weakness and dizziness. Overall, most signs and 
symptoms will not appear until the arteries are severely narrowed or blocked. 
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6.2.3 Diagnosis 
The most commonly performed non-invasive testing method for blood flow 
limitations is cardiac stress testing.207 In this method, the heart’s ability to respond to an 
external stress, induced by exercise or drug stimulation, is measured. Usually a treadmill, 
stationary bicycle or hand crank will be used to testing.  
Angiography is another common method where the lumen of blood vessels is 
visually examined by injecting a radio-opaque contrast agent into the blood vessel.208 The 
vessels are imaged using X-ray based techniques. This is particularly useful for blood 
vessels near the heart and brain. Examples of arteries before and after treatment can be 
seen in Figure 63.209 
 
Figure 63: Angiographs of arteries before treatment (above images) and after treatment (lower images) 
illustrating narrowing of arteries and blood flow.209 
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Nuclear stress tests are implemented to visualize the blood flow after injection of 
a radiotracer. This test will identify regional areas of reduced blood flow. If a patient has 
ECG abnormalities or severe motor disability, this test can cause stress and cardiac 
damage. 
For most artery flow disruptions, the lumen (inside space of tubular structure, 
such as artery) is narrowed by less than 50% at these locations. In cardiac stress testing, 
the detection limit is for 75% or greater lumen narrowing. Nuclear stress methods may be 
able to detect as little as 50%. 
6.2.4 Risk Factors 
While the exact cause of atherosclerosis is unknown, there are certain traits, 
conditions or habits that can increase an individual’s likelihood of acquiring it.210 A 
number of these can be controlled or monitored to prevent or delay atherosclerosis while 
others are entirely unavoidable. 
The formation of plaques is dependent upon LDL and HDL. The levels of both 
LDL and HDL in the bloodstream can be indicators of the chance of atherosclerosis. 
High LDL and low HDL levels increase the risk of plaque development as these are 
integral in the formation cycle. Other factors which increase a person’s risk of 
atherosclerosis are high blood pressure, smoking, insulin resistance, diabetes, obesity or 
overweight, lack of activity, age and family history of early heart disease.211 With high 
blood pressure, more force is exerted on the arteries in your body leading to more serious 
problems. If a person smokes, the blood vessels in the body can be damaged or tightened. 
It also raises cholesterol levels and blood pressure. As the body ages, the signs and 
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symptoms of atherosclerosis begin to appear. For men, risk increases after age 45 while 
for women, it is after age 55.  
6.2.5 Treatments 
When attempting to provide treatment for atherosclerosis, doctors endeavor to 
lower risk factors or if the condition is more severe, they will elect for a surgical option. 
There are a variety of risk factors that can be controlled with pharmaceuticals; others can 
be simply a lifestyle change such as not smoking or performing regular exercise. 
6.2.5.1 Statins 
One common method is the prescription of a type of drug called a statin. Statins 
function by competitively inhibiting HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase).72 In the mevalonate pathway producing cholesterol, HMG-CoA 
reductase is the rate-controlling enzyme.212 Statins are similar in structure to HMG-CoA 
on a molecular level enabling them to bind to the enzyme’s active site competing with 
HMG-CoA. Effectively, the rate at which mevalonate is produced in decreased creating a 
cascade effect through the pathway lowering the amount of cholesterol manufactured as 
seen in Figure 64.212 
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Figure 64: Mevalonate pathway where cholesterol is produced. Statins interfere with this process by 
interacting with HMG-CoA reductase binding preventing further assembly of cholesterol.212 
 
Statins have only been marketed in the last thirty years as initial research to 
discover a cholesterol-lowering drug began in 1971 by Akiro Endo working for Sankyo. 
His team extracted mevastatin from the fungus Penicillium citrinum. The drug was never 
marketed as it caused serious side effects of tumors, muscle deterioration and even death. 
In 1978, Merck isolated lovastatin from the fungus Aspergillus terreus, but it was not 
marketed for 9 years until 1987 as Mevacor. Nowadays, there are numerous statins 
available on the market as shown in Table 8, with varying degrees of potency.  
Table 8: Statin Drugs Available as Pharmaceuticals 
Statin Structure Brand 
Name 
Derivation Year 
Approved 
Atorvastatin 
 
Lipitor, Ator Synthetic 1996 
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Table 8 continued 
Statin Structure Brand 
Name 
Derivation Year 
Approved 
Cerivastatin 
 
Lipobay, 
Baycol 
(removed 
from market 
in 2001 due 
to severe 
side effects) 
Synthetic 1997 
Fluvastatin 
 
Lescol Synthetic 1994 
Lovastatin 
 
Mevacor, 
Altocor, 
Altoprev 
Natural 1987 
Mevastatin 
 
Compactin Natural Never 
marketed 
Pitavastatin 
 
Livalo, 
Pitava 
Synthetic 2003- 
Japan, 2009 
- US 
Pravastatin 
 
Pravachol, 
Selektine, 
Lipostat 
Natural 1991 
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Table 8 continued 
Statin Structure Brand 
Name 
Derivation Year 
Approved 
Rosuvastatin 
 
Crestor Synthetic 2003 
Simvastatin 
 
Zocor, 
Lipex 
Synthetically 
produced, but 
is found in 
natural 
process  
1989 
 
6.2.5.2 Prescribed Pharmaceuticals to Lower Risk Factors 
To prevent blood clots, doctors may prescribe aspirin as an anti-platelet 
medication. It attempts to avert further harmful blockages. To lower an individual’s blood 
pressure, a variety of drugs can be utilized. Beta-blockers lower the heart rate and blood 
pressure, reducing the risk of heart attacks and heart rhythm problems. Other medications 
which lower the blood pressure include calcium channel blockers, diuretics, and 
angiotensin-converting enzyme (ACE) inhibitors.  
6.2.5.3 Surgical Options 
When the atherosclerosis begins to show signs of severe symptoms or blockages 
threatening survival, doctors will opt for more aggressive treatments. One common 
method is angioplasty where an empty, deflated balloon (balloon catheter) is passed over 
a wire into specific locations. The balloon is inflated to a desired size, expanding vessels 
to improve blood flow and compresses the plaque deposits.213 Occasionally, a mesh tube 
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(stent) will be placed in the artery to ensure it remains open. A diagram of this procedure 
visualizes the process in Figure 65. 
 
Figure 65: Procedures for balloon angioplasty and stent angioplasty. The main difference is whether or not 
a structural device (stent) is left behind to help maintain flow through the artery. 
 
In other cases, the fatty deposits need to be surgically removed from the artery in 
a process called endarterectomy. In this procedure, an incision is made on the body to 
locate the artery with deposit. The vessel is clamped around the deposit to open it and 
remove the fatty deposit entirely. The artery is closed and patched after deposit removal. 
This commonly occurs for the carotid artery. 
Instead of removal of a deposit, a doctor may elect to perform a bypass surgery. 
In this method, a vessel from another part of the body or a tube made of synthetic fabric 
is used to allow blood to flow around the blocked or narrowed artery.  
6.3 Cholesterol Structure 
Cholesterol is capable of forming multiple polymorphs depending on the growth 
conditions. The two most common ones are cholesterol monohydrate and anhydrous 
104 
cholesterol. Cholesterol monohydrate crystals have a bilayer structure with space group 
P1. In their triclinic structure, the polar 3-hydroxyl ends form hydrogen bonds with each 
other and water molecules. The unit cell crystallographic dimensions are as follows: a = 
12.39 Å, b = 12.41 Å, c = 34.36 Å, α = 91.9o, β = 98.1o, and γ = 100.8o.214 These crystals 
exhibit a platelike morphology, which can be seen in Figure 66.215 The largest plate face 
is the c face, or (001) face, which is a result of faster growth within the bilayer plane than 
growth between bilayers. This is an effect of stronger intermolecular interactions in the 
bilayer plane.  
 
Figure 66: Photo of cholesterol monohydrate crystal depicting the platelike morphology.215 
 
Anhydrous cholesterol crystals are triclinic with a space group of P1 similar to 
cholesterol monohydrate. The unit cell dimensions are a = 14.17 Å, b = 34.21 Å, c = 
10.48 Å, α = 94.6o, β = 90.7o, and γ = 96.3o.216 The observed morphology is clearly 
distinct from cholesterol monohydrate as needlelike crystals are produced as seen in 
Figure 67.215  
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Figure 67: Anhydrous cholesterol crystals illustrating needlelike morphology.215 
 
Polymorphs of anhydrous cholesterol can be produced depending on the 
conditions. One method is the loss of water from the crystal structure of cholesterol 
monohydrate. To rehydrate the crystal back to the original cholesterol monohydrate, at 
least 24 hours were required and the rate of hydration was dependent on the polymorph 
of anhydrous cholesterol.215 Figure 68 illustrates the differences in rate of hydration. 
 
Figure 68: Rate of hydration of cholesterol in bulk water. Blue circles represent anhydrous cholesterol and 
water equilibrated at 20oC and yellow diamonds are anhydrous cholesterol and water at 
45oC.215 
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Depending on the system, cholesterol solubilizes in varying quantities. Sonicated 
systems of synthetic homogenous chain lecithins have been shown to solubilize up to 3 
moles of cholesterol for every 1 mole of phospholipid.217 Liposomes produced from 
certain organic solvents contain about 2 moles of cholesterol in 1 mole of phospholipid in 
a metastable state.218 The solubility limit of cholesterol in phospholipids is attributed to 
the molecule’s intrinsic hydrophobicity and the interactions between the sterol hydroxyl 
group with the polar moiety of the lipid.219,220  
6.4 Methods of Crystallization 
To crystallize anhydrous cholesterol, pure cholesterol is dissolved in hot acetic 
acid.215 The solution is then cooled slowly to change the solubility and crystallization to 
occur. To isolate the crystals, the solution was filtered on filter paper and placed in an 
80oC heated desiccator under vacuum to remove any lingering acetic acid. The crystals 
were stored in the dark in a desiccator over phosphorus pentoxide at 4oC. 
To grow cholesterol monohydrate crystals, a method of slow evaporation over 10 
days from solutions of 95% ethanol and 5% distilled water has been utilized. During the 
slow evaporation process, platelike crystals began to form. The crystals are originally 
transparent or clear, but after a few hours of exposure to air a transformation to opaque 
crystals transpires due to dehydration of the crystalline structure. It is desired to extract 
hydrated crystals for experiments before dehydration occurs or implement another 
method of storage. To prevent autoxidative degradation221,222, crystals can be stored in 
water in the dark at 4oC for up to three months.  
Using thermogravimetric analysis, the amount of water in a known mass of 
crystals can be determined by increasing the temperature while monitoring the mass of 
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the sample. For anhydrous cholesterol crystals, there is no change in mass; however, 
cholesterol monohydrate crystals experience a loss of mass, which can be attributed to 
water in the crystalline structure.  
Other groups have attempted to uncover relationships between the solvent utilized 
for crystallization and its effect on the polymorph and morphology of cholesterol crystals 
produced. In one study, the morphology of cholesterol crystals grown in methanol, 
ethanol, acetone, and acetonitrile with 5% water and as extra dry pure solvents was 
examined. For these experiments, supersaturated solutions were produced by heating the 
solutions and then after a reduction of temperature at a rate of 4oC per hour, cholesterol 
crystals formed. Needlelike crystals form in solutions of methanol and acetonitrile and in 
pure acetone. If anhydrous ethanol is used, cholesterol hemiethanolate crystallizes as the 
solvent is occluded in the structure. The angles of these crystals (71o and 110o) differ 
from cholesterol monohydrate (79o and 100.8o) as shown in Figure 69. Cholesterol 
monohydrate crystals form in 95% ethanol with 5% water and 95% acetone with 5% 
water.  
 
Figure 69: Cholesterol crystals. (A) Grown from pure ethanol and (B) 95% ethanol with 5% water.223 
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Lia Addadi and coworkers wanted to demonstrate cholesterol crystallization from 
two-dimensional domains in lipid bilayers.224 Cholesterol is known to be an essential 
lipid in vertebrates as it is involved in membrane structure and function; yet to transport 
this molecule to various parts of the body, it requires assistance.6 In this method, lipid 
bilayers with varying compositions and two-dimensional cholesterol domains function as 
nucleation sites for three-dimensional cholesterol crystals. However, these crystals only 
nucleate if there are domains of cholesterol in the lipid bilayers. For this system, it 
requires a three-phase setup as shown in Figure 70. The lipid bilayers were supported on 
coverslips which float on an aqueous phase. The aqueous phase contains methyl-β-
cyclodextrin, which acts as a carrier of cholesterol. Beneath the aqueous solution, a 
saturated cholesterol solution in chloroform exists as a source where the cyclodextrin 
extracts cholesterol and transports it to the bilayers on the coverslip. Attempts to remove 
the crystals produced from the lipid bilayers failed suggesting the embedment of crystals 
in the bilayers. Most of the crystals produced by this method were cholesterol 
monohydrate parallelogram-shaped plates, yet some appeared as curved cylindrical 
particles and transformed into plates over a longer time. If the cholesterol in the bilayer 
did not segregate into domains but remained homogeneous throughout the lipid bilayer, 
no crystals were formed.  
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Figure 70: Three-phase setup for growth of cholesterol crystals with transport from an organic source 
across an aqueous medium to lipid bilayers.224 
 
In contrast, others believe the direct formation of platelike cholesterol 
monohydrate crystals is incorrect. In a study by Martin Carey and coworkers, they 
utilized a model bile system composed of taurocholate, egg yolk lecithin and cholesterol 
in a molar ratio of 97.5:0.8:1.7. The model bile was dissolved or diluted to a specific 
concentration to create micelles and vesicles. Between 2–4 hours after dilution, thin 
filamentous structures were observed by optical, fluorescence and scanning electron 
microscopy. Within 12 to 24 hours, the filaments had aggregated into “wheat sheaf” 
bundles. Over the course of days, the progression from filaments to other structures 
occurs. During 2–7 days, thicker needlelike and helical structures appear along with 
platelike crystals. In videos of optical microscopy, the filaments coiled into spirals and 
helices which eventually formed tubelike structures. These tubes fractured at the ends to 
produce platelike crystals. Occasionally, the filaments would grow into flat ribbons, 
which will subsequently break directly into plates. Also, platelike crystals were produced 
without any transitions. This transformation of crystals is illustrated in Figure 71.225 
Using X-ray diffraction, the cholesterol crystal polymorph produced at various stages can 
be verified. The filaments exhibit peaks from anhydrous cholesterol crystals at 8-12 hours 
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in addition to cholesterol monohydrate peaks; however, only cholesterol monohydrate 
was detected after 24 hours.  
 
Figure 71: Illustration of transformation of crystals from filaments to ribbons, spirals or helices to plates.225 
 
Although the growth medium described above is not physiological, other 
compositions of model biles were tested along with human gallbladder biles to evaluate 
their physiological relevance. The other systems experienced similar transformations 
from filaments to plate crystals. However, it should be noted this phenomenon has never 
been observed for atherosclerosis plaques or biomimetic models.  
Prior studies in the literature have predominantly focused on the lipids present in 
the gallbladder and how they affect the crystallization of cholesterol. To date, there  lacks 
fundamental systematic analyses of cholesterol crystallization. Dissolution has been 
observed using in situ AFM, but growth has not, leaving the mechanism of crystallization 
unknown. Therefore, this project attempts to address these unanswered questions. 
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Chapter 7: Solution Properties of Cholesterol in Various Solvents 
Before elucidating the growth mechanism of cholesterol crystals, a 
physiologically-relevant solvent (growth medium) must be identified. The solvent should 
possess similar characteristics of both environments of gallstones and atherosclerosis. 
With this in mind, the search for a biomimetic environment(s) was the first major 
objective of this project. 
7.1 Solubility of Cholesterol 
The solubility of cholesterol determines how crystallization occurs in the body. 
Variations in cholesterol solubility emerge as the concentrations of lipids are altered 
based on biological responses of the body. These are observed in ternary diagrams of bile 
salts, phospholipids and cholesterol as well as the compositions of phospholipids in 
membranes. For all of these techniques, micelles, vesicles or lipid bilayers serve as 
potential heterogeneous interfaces for cholesterol crystals to grow and/or adhere. 
However, these systems are difficult to mimic for AFM measurements. As such, alcohols 
with varying chain length (as lipid surrogates) were selected and the percentage of water 
dissolved in the alcohol was adjusted to tune cholesterol solubility. Alcohols contain both 
a hydrophilic and hydrophobic moieties similar to lipids and are capable of solvent 
structuring. 
7.1.1 Preparation of Alcohol Solvents 
Initially, methanol, ethanol, butanol, hexanol and octanol were chosen as suitable 
solvents for investigation. Alcohols larger than octanol (8-chain length alcohol) are more 
susceptible to phase change with temperature variation. For example, decanol (10-chain 
length alcohol) can easily change from liquid to solid depending on slight fluctuations in 
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temperature. Therefore, no alcohols with a chain length larger than octanol were 
investigated. The water solubility in each solvent was tested to evaluate the percentages 
of water to test for cholesterol solubility.  
Fresh deionized water was added to 20 mL glass vials with alcohols creating 10 
mL solutions with varying percentages of water by volume. The solutions were allowed 
to equilibrate over the course of two days with occasional stirring to ensure mixture of 
water into the alcohol. If droplets were present after this time, the solution was 
considered immiscible at that volume percentage of water. Methanol and ethanol were 
miscible at all volume percentages of water. Butanol is miscible up to 15% by volume 
(i.e, a 20% solution was two-phase). For hexanol, water becomes immiscible at 
approximately 7.5% by volume of water. The solubility of water in octanol was found 
earlier to be 2.7 mol kg-1 (3.85% v/v). 
The pH of blood is 7.35–7.45 while the pH of gallbladder bile is between 5.6 and 
8.0. As an attempt to vary the aqueous solution present in the alcohol, phosphate buffer 
(pH 5.6) was added in varying percentages by volume to ethanol. At 30% v/v in ethanol, 
the phosphate precipitates out of solution. Therefore, solubility determination for this set 
with phosphate buffer was discontinued. 
7.1.2 Extinction Coefficients of Cholesterol 
To measure the solubility in these environments, two different methods were 
employed. In the first method, the Beer-Lambert Law (Equation 1) and UV-Vis 
spectrophotometry were employed; however, the extinction coefficients for each solvent 
with varying percentages of water needed to be determined first. 
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A known mass of cholesterol was dissolved in a fixed volume of solvent in a glass 
vial. The solution was allowed to sit for at least one day in the dark at 25oC to ensure full 
dissolution. The solution in the vial was examined in an inverted microscope to ensure no 
solid residue was lingering. The entire solution was filtered with a 0.2 µm 
polytetrafluoroethylene (PTFE) filter. The filtered solution was diluted with filtered 
solvent (0.2 µm PTFE filter) to make ten different concentrations. The absorbance 
spectrum of each solution was measured from 200-800 nm in a quartz cuvette designed 
for this wavelength range. Peaks were chosen for each spectrum for every solvent. The 
absorbance at this peak was plotted as a function of concentration. This method was 
performed in triplicate for each solvent. The extinction coefficient for each solvent was 
calculated from this data. All of the extinction coefficients for cholesterol can be seen in 
Figures 72-74 and Table 9. For all regression analysis, the intercept was forced to go 
through the origin and any absorbance values above 1.1 were not included as the Beer-
Lambert Law tends to fail above this region as an effect of turbidity. 
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Figure 72: Extinction coefficients of cholesterol in methanol and ethanol based solvents. Insets are spectra 
of cholesterol in the designated solvent. 
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Figure 73: Extinction coefficients of cholesterol in butanol based solvents. Insets are spectra of cholesterol 
in the designated solvent. 
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Figure 74: Extinction coefficients of cholesterol in hexanol and octanol based solvents. Insets are spectra 
of cholesterol in the designated solvent. 
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Table 9: Extinction coefficients of cholesterol in various solvents 
 
Solvent ε [mM-1cm-1] λ  [nm] 
Methanol 4.11 ± 0.08 201 
Ethanol 3.36 ± 0.06 202 
Ethanol + 5% H2O 4.10 ± 0.04 202 
Ethanol + 7.5% H2O 4.6 ± 0.2 201 
Ethanol + 10% H2O 5.10 ± 0.09 201 
Butanol 2.87 ± 0.05 204 
Butanol + 2.5% H2O 3.03 ± 0.05 204 
Butanol + 5% H2O 3.56 ± 0.08 203 
Butanol + 7.5% H2O 3.81 ± 0.07 203  
Hexanol 2.30 ± 0.04 205 
Hexanol + 2.5% H2O 3.54 ± 0.08 204 
Hexanol + 5% H2O 2.73 ± 0.05 205 
Octanol 3.24 ± 0.06 202 
 
7.1.3 Measuring Cholesterol Solubility 
After determining the extinction coefficients, the solubility of cholesterol in each 
solvent could be measured. In 20 mL glass vials with septum caps, excess cholesterol 
powder was added to 3-5 mL of solvent. For each solvent, three separate vials were 
prepared to ensure reproducibility. All of the vials were stored in the dark at 25oC. The 
only exceptions were for ethanol with 5% H2O, ethanol with 7.5% H2O and ethanol with 
10% H2O where a temperature dependence of solubility was observed. For those systems, 
three vials were made for each separate temperature. After one week of equilibration, 
every vial was examined to ensure powder was still present. If all of the solid cholesterol 
had dissolved, more powder was added to each vial. After two weeks and three weeks of 
isolation, 0.2 mL of solution was filtered through a 0.2 µm PTFE filter. The filtered 
solutions were diluted to acceptable concentration for UV-Vis spectrophotometry 
(absorbance less than 1.0 and greater than 0.5) and the absorbance spectra were 
measured. All dilutions used filtered solvent and the spectra were blanked with filtered 
solvents. The solubility was tabulated for each solvent at all temperatures. In Figure 75, 
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cholesterol solubility is compared between all solvents at 25oC from the Beer-Lambert 
Law method.  
 
Figure 75: Solubility of cholesterol in various solvents (alcohols) with varying percentages of water 
determined using the extinction coefficients and the Beer-Lambert Law. 
 
The second method for determining the solubility of cholesterol is monitoring the 
dissolution of cholesterol over time. A known mass of cholesterol was placed in a 20 mL 
glass vial with a septum cap with a specific volume that will not cause full dissolution of 
the solid powder. Every three or four days, the vial was examined to see if full dissolution 
had transpired. If solid remained, a small amount of solvent was added to the vial. If it 
appeared as though all the cholesterol had dissolved, the vial was observed underneath an 
inverted microscope to ensure full dissolution. More solvent was added to each vial until 
full dissolution occurred. This process lasted for over 30 days for some solvent systems. 
At this time, the solubility was calculated by the known mass of cholesterol at the 
beginning of the experiment compared to the total volume of solvent necessary for 
dissolution. Errors for this method arise due to dissolution at a lower volume than the 
increment addition. Only one vial was prepared and monitored for each solvent at 25oC. 
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The results could be reproducible, but they were not performed at this time. In Figure 76, 
the solubility of cholesterol from the dissolution method can be viewed. 
 
Figure 76: Solubility of cholesterol at 25oC in alcohol solvents with varying volume percentages of water 
determined by monitoring the dissolution of cholesterol powder over time. 
 
When comparing the solubilities measured between the two methods, the values 
tend to be similar with a few exceptions in hexanol and octanol solvents. Notably, the 
solubility of cholesterol in octanol appears higher with the extinction coefficient method 
than with the dissolution method. Hofmann and coworkers observed a maximum 
solubility of cholesterol in pure alcohol solvents at approximately 7-carbon chain length. 
I observe a downward trend after an increase in the solubility using the dissolution 
method, but discern only an increasing trend with the extinction coefficient procedure. 
This could be due to the limited samples when performing dissolution or high solubility 
of cholesterol in octanol. It is possible to identify the same maximum at the 7-carbon 
chain length if the solvents are extended to odd chain length alcohols and longer chain 
lengths. If we assume this trend occurs in this system, the solubility present in 
phospholipids characteristic of gallstones and atherosclerosis would be similar to the 
solubility observed with ethanol. 
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For hexanol, the solubility of cholesterol with 2.5% water dissolved varies 
between the two methods as they show opposite trends. To verify if these values are 
reproducibly detected, the solubility of cholesterol in hexanol with 1.25% and 3.75% 
water could be found using extinction coefficients or dissolution. For the dissolution 
method, more trials could be performed to duplicate the previous experiments. 
The solubility of cholesterol in the gallbladder ranges from 5-50 mM. The only 
alcohol with corresponding solubility to the values in the body is ethanol; therefore, I 
selected ethanol for all subsequent studies.  
 
Figure 77: Temperature dependence of the solubility of cholesterol in ethanol with varying percentages of 
water dissolved in the solvent. 
 
The effect of temperature on the solubility of cholesterol was evaluated in ethanol 
containing 5, 7.5 and 10% water as shown in Figure 77. For all three systems, the 
solubility increases as temperature increases. If the solubility is converted using the van’t 
Hoff equation (Equation 9), the enthalpies and entropies of crystallization of cholesterol 
can be assessed. These values are listed in Table 10.  As the volume percentage of water 
dissolved in ethanol increases, the enthalpy of crystallization decreases. However, the 
errors of these values show some overlap (particularly at higher water content). Overall, 
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these values can be utilized to assess if crystallization of cholesterol is governed by 
thermodynamics.  
Table 10: Thermodynamics of crystallization of cholesterol 	  
Solvent ΔH [kJ mol-1] ΔS [J mol-1K-1] 
EtOH + 5% H2O -26 ± 2   115 ± 7 
EtOH + 7.5% H2O -30 ± 1   126 ± 4 
EtOH + 10% H2O  -32 ± 4   115 ± 7 	  
The gallbladder and blood contain both aqueous and organic media. If the 
solubility of cholesterol in water is compared to the solubility in ethanol, the difference is 
more than five orders of magnitude as shown in Figure 78. The putative low solubility in 
water demonstrates the difficulties with crystallization in an aqueous environment. The 
degree of supersaturation that can be achieved is limited, thus hindering crystallization. 
The high solubility of cholesterol in ethanol enables a supersaturation to be achieved 
easily with rapid crystallization. 
 
Figure 78: Comparison of the solubility of cholesterol at 25oC in water versus ethanol. 
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Chapter 8: Bulk Crystallization & AFM Studies 
Initially, I wanted to survey the differences between crystals grown in a purely 
aqueous medium to an organic medium. The only growth procedures in an aqueous 
solution in the literature contain some amount of lipid or organic solution. Therefore, I 
had to use an approach to dissolve a sufficient quantity of cholesterol to create a 
supersaturated solution for growth. 
8.1 Purely Aqueous Environment 
Using a phosphate buffer at pH 5.6, a 1.2 mM solution of cholesterol was made in 
a 10 mL round bottom flask. The solid did not dissolve as expected; therefore, the 
solution was refluxed at 125oC (oil bath temperature) for 2 hours. The temperature was 
decreased by 5oC every hour until the temperature was 100oC. The solution was refluxed 
for another hour before the solution was filtered through a 0.45 µm Supor filter paper 
with a 47 mm diameter. The filter paper was rinsed with deionized water and placed in a 
glass petri dish in a 37oC oven to dry.  
The time for reflux was adjusted to allow for longer crystallization time. The 
heating bath was initially set at 125oC for 17 hours and subsequently lower by 5oC every 
2 hours until reaching 100oC. The flask remained in the oil bath for another 13 hours 
before filtration. The crystals produced from this method can be seen in Figure 79. Few 
crystals were found on the filter paper and uniformity of crystal morphology could not be 
detected. This finding reinforces the requirement of an organic medium for crystallization 
of cholesterol in the body. There was insufficient powder to perform XRD and determine 
which polymorph of cholesterol crystallized from the aqueous solution.  
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Figure 79: Cholesterol crystals grown from a phosphate buffer, pH 5.6, at reflux with a slow cooling rate. 
8.2 Ethanol Solvents 
Several methods have been previously described to grow cholesterol monohydrate 
crystals in ethanol with 5% water with timescales ranging from only a few hours to 
weeks. One protocol requires a special crystallization cell with a controlled heated water 
bath to slowly lower the temperature while another protocol allows slow evaporation to 
change the supersaturation in solution. Using this knowledge, I could begin to develop 
similar procedures to grow cholesterol crystals. 
Initially, I dissolved cholesterol powder in 4 mL of an organic solvent in a 20 mL 
glass vial with a septum cap. The vial was sealed with a layer of parafilm and placed in a 
60oC oven to fully dissolve the solid. Depending on the concentration of cholesterol, the 
amount of time the vials spent in the oven ranged from 1.5-12 hours to allow full 
dissolution. The vials were removed and stored at 25oC in the dark. After 24 hours, the 
vials were filtered through a 0.45 µm Supor filter paper with a 47 mm diameter. The 
filtration system was cleaned thoroughly and rinsed with ethanol to ensure no water was 
present during separation. If any water is present, the solution will precipitate cholesterol 
instantaneously. The filter papers were placed into plastic petri dishes to dry at 23oC. 
Examples of cholesterol crystals grown with this method are shown in Figure 80. 
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Figure 80: Optical microscopy images of cholesterol crystals grown from (left to right) 64.1 mM in 
ethanol, 30.0 mM in ethanol with 5% water, and 15.0 mM in ethanol with 10% water. 
 
This method readily produces cholesterol crystals, but control over the 
polydispersity is limited as sizes vary greatly. To circumvent this problem, I examined 
the effect of crystallization time, supersaturation, isolation techniques and cooling rate 
after characterization of the crystal structure to determine which polymorph of 
cholesterol crystallizes. 
To characterize the crystals, I made large batches of crystals with supersaturation 
ratios (C / Ce) between 1.5 and 2. After filtration and drying, I crushed the crystals into a 
fine powder with a mortar and pestle. Using XRD (Siemens D5000 X-ray Diffractometer 
with a CuKα radiation source [40 kV, 30 mA, 1.54 Å]), the crystal structure of samples 
grown from each solvent could be determined. The effects of drying on the structure of 
the crystals were observed. At various hour intervals of drying at room temperature, the 
recovered solid could be crushed into a powder. One powder sample was also dried at an 
elevated temperature of 37oC to check for any structural transformation. In Figure 81, the 
XRD patterns are compared for different drying times for as synthesized crystals 
prepared from ethanol with 5% water growth solutions.  
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Figure 81: XRD patterns of cholesterol crystals grown from ethanol with 5% water after varying drying 
times with model patterns produced from Diamond. At 0 hours, the crystals are hydrated, but 
after 3 days at 37oC, the crystals are fully anhydrous. 
 
As water evaporates from the crystals, there are distinct changes in Bragg 
peaks(i.e., some peaks disappear and new peaks arise, indicating a change in the 
crystalline structure). The hydrated crystal XRD pattern resembles the monohydrate 
model with d-spacings of the crystals matching the models (Figure 82). When fully dry, 
the crystals are anhydrous cholesterol, which matches previous literature stating water 
exits the crystal structure. When examining the crystals under an optical microscope for 
long periods of time, the surface slowly shifts from transparent to opaque. This 
emphasizes how storage and longevity of crystals will impact future experiments.  
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Figure 82: Cholesterol crystal grown in ethanol with 5% water exhibiting dihedral angles characteristic of 
cholesterol monohydrate. 
 
Similar XRD experiments were performed for cholesterol crystals prepared from 
ethanol with 10% water growth solutions. The results are shown in Figure 83. The 
patterns are consistent with those from ethanol with 5% water in Figure 81. The 5% 
difference in water dissolved in ethanol has no apparent effect on the type of cholesterol 
crystallized from solution. 
 
Figure 83: XRD patterns of cholesterol crystals grown from ethanol with 10% water after varying drying 
times. 
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8.2.1 Effects of Growth Conditions in Ethanol with 5% H2O 
The growth of crystals can be controlled by a variety of factors. To produce 
uniform (i.e., low polydisperse size) crystals, I methodically adjusted the crystallization 
time, supersaturation and rate of cooling individually. Initially, I examined how the 
length of crystallization time affects the crystals (see Figure 84). The length of time is 
measured as time after removal from the oven to cause supersaturation until the solution 
is filtered. At time zero there are no crystals as expected but the length of time for 
crystallization of a 29.7 mM cholesterol in ethanol with 5% water did not provide 
uniform crystals. There was also lack of reproducibility between samples prepared under 
the same conditions. 
 
Figure 84: Effect of crystallization time for 29.7 mM cholesterol growth solution over the course of 24 
hours. Scale bar is 100 µm. 
 
Next, I adjusted the degree of supersaturation of the growth solution with a 
constant growth time of 24 hours (Figure 85). The growth solution concentrations ranged 
from 23.9 to 31.3 mM cholesterol. If the supersaturation is too high, the filter paper is 
completely covered with crystals, which are indistinguishable from each other in optical 
micrographs. With these conditions, reproducibility does not occur and the sizes of 
crystals vary from tens of microns up to a few millimeters.  
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Figure 85: Optical micrographs of cholesterol crystals grown from varying degrees of supersaturations in 
ethanol with 5% water. 
 
The driving force of crystallization is supersaturation, and adjusting the rate of 
cooling can decrease or increase supersaturation. With a lower cooling rate, the net 
change in supersaturation is slower enabling the growth rate of crystals to be more easily 
controlled. For the next set of experiments, the glass vials were placed in a water bath 
circulator after dissolution in the oven. The initial temperature was 50oC with incremental 
decreases in temperature over 8 hours. Every hour, the temperature was lowered by 5oC 
until reaching 35oC. Then, the temperature was reduced by 2oC every hour until reaching 
25oC where the vials were then transported to the 25oC drawer outside of the water bath 
circulator. The solutions were allowed to crystallize for another 19 hours at 25oC before 
filtration. The crystals produced with this method at varying supersaturation can be 
viewed in Figure 86. Under these conditions, few crystals appear at concentrations less 
than 25 mM cholesterol (each with indistinct morphologies). However, above 27 mM 
cholesterol, low polydisperse (uniform) crystals can be seen. Therefore, this method 
seems to be effective at creating crystals with a low polydispersity. In this method, the 
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vials are agitated (in the water bath) as the water circulates, causing discrepancies 
between sample batches.  
 
Figure 86: Cholesterol crystals produced using a slower cooling rate in a water bath circulator with several 
growth concentrations.  
 
To decrease agitation, the type of water bath was switched to a simple setup as 
shown in Figure 87. The temperature of the heated water bath was measured with a 
mercury thermometer during the experiment. After removal from the oven following 
dissolution, the temperature of the water bath was maintained at 55oC for one hour. The 
temperature of the water bath is lowered every hour by 6–7oC until approximately 29oC. 
For at least three hours, this temperature is maintained then changed to 23oC. Solutions 
were filtered after another 16 hours of crystallization. 
 
Figure 87: Setup of the water bath with vials used to produce cholesterol crystals with limited agitation and 
a slow cooling rate. 
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In Figure 88, the cholesterol crystals produced with limited agitation and a slower 
cooling rate can be seen. For these samples, lower supersaturation results in reduced 
polydispersity and larger crystals compared to those produced at high supersaturation. As 
the concentration of cholesterol increases, the number of distinguishable single crystals 
decreases. However, the number of crystals present on the filter paper increases as the 
supersaturation increases. With this method, the reproducibility between samples is 
improved and outlier crystals of larger size are observed less frequently at higher 
cholesterol concentrations. 
 
Figure 88: Microscope images of cholesterol crystals grown using a water bath with limited agitation and a 
slow cooling rate. 
 
In summary, this method proves to be useful for further studies of bulk 
crystallization and in situ AFM measurements. The supersaturation of the solution, 
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cooling rate temperatures, and time of cooling can be adjusted to yield crystals with 
desirable features depending on what is vital for the experiment. 
8.3 AFM Surface Studies 
To begin AFM surface studies, the crystals produced with the bulk crystallization 
methods needed to be mounted on metal AFM specimen disks. Jennifer Swift and 
coworkers working with cholesterol monohydrate utilized epoxy to attach large crystals 
for in situ AFM dissolution studies.226 For my studies, I attempted to use a variety of 
epoxies as well as directly attach the crystals to glass.  
Cholesterol monohydrate crystals do not adhere to the surface of glass coverslips 
during growth. The glass coverslip’s surface is hydrophilic while the crystals are 
hydrophobic, which prevents attachment. To bypass this, I functionalized the surface of 
glass coverslips with (7-octan-1-yl) trimethoxysilane. After silanization, water droplets 
placed on the surface of the coverslips did not spread across the glass (contrary to the 
non-functionalized surface). However, cholesterol crystals did not grow on the surface of 
silanized glass coverslips regularly and required higher supersaturation growth solutions. 
More crystals formed in solution instead of on the glass. If a crystal attached to the 
surface, it could not be used for in situ AFM as crystals immediately detached in growth 
solutions. 
Before trying to press crystals into epoxy on AFM disks, I tested each epoxy’s 
compatibility with ethanol. In almost all of the epoxies, swelling prevented further usage. 
However, Norland Optical Adhesive 81 (ultraviolet cure glue) was not impacted by the 
presence of ethanol and was used for AFM studies. 
132 
 
Figure 89: AFM images of cholesterol monohydrate crystals.  
In Figure 89, the surface of a cholesterol monohydrate crystal in air can be 
viewed. I used a Multimode atomic force microscope (Nanoscope IV) from Digital 
Instruments. AFM images were captured in tapping mode using Olympus TR800PSA 
probes (Silicon nitride, Cr–Au coated, with spring constant 0.15 N/m). The resonance 
frequency for tapping mode would fall into two ranges for imaging in solution: 100-130 
kHz and 340-370 kHz. I collected images in height and amplitude modes with 256 scan 
lines per image. Cholesterol monohydrate crystals are soft and easily altered by contact 
mode imaging with the AFM tip. The surface can be etched away with a single pass 
across the imaging area. As a result, contact mode imaging could not be used for any 
experiments; only tapping mode would not impact the surface features.  
 
Figure 90: Flattened AFM height image depicting layers on the surface of a cholesterol monohydrate 
crystal on the left. The right image is the amplitude mode of the same surface.  
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In tapping mode, the surface of the crystals could be analyzed and imaged as 
shown in Figure 90. With height images, the step heights can be measured to determine if 
the crystal structure matches the unit cell of cholesterol monohydrate. In Figure 91, the 
frequency of step heights can be seen. This histogram illustrates how the step heights 
roughly correlate to expected step values of half step, step and step bunches of 
cholesterol monohydrate crystals in the c-direction (3.4 nm).  
 
Figure 91: Histogram of measured step heights from cholesterol crystals from flattened AFM height 
images. 
 
Half step values occur due to the packing of cholesterol monohydrate structures. 
In the c-direction, two cholesterol molecules are stacked linearly as demonstrated in 
Figure 92. The determination of the growth mechanism of cholesterol monohydrate 
would likely provide insight as to how molecules incorporate into the crystalline 
structure. If single monomers are added (i.e., classical crystallization), the steps will 
propagate as half step heights. In contrast, dimers or oligomers could bind to surface sites 
causing the crystal to grow nonclassically.  
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Figure 92: Model of unit cell of cholesterol monohydrate. C-direction is upward illustrating how 
cholesterol molecules stack with hydrogen bonding. 
 
For in situ AFM studies, the method of mounting crystals to the AFM disk has a 
huge impact on whether dynamic surface events will occur. If the glue is not tacky 
enough, any crystals mounted in the glue will detach as soon as the growth solution is 
pushed into the AFM liquid cell. Pressing the crystals into glue that is excessively tacky 
will not allow any solution to have an effect on the crystals. For example, pure ethanol 
was used to dissolve the crystals as the solubility of cholesterol is double in this solvent 
compared to ethanol with 5% water. However, the crystal will not indicate any signs of 
dissolution or change in the surface whatsoever. Therefore, the optimal method for 
crystal attachment is as follows. Norland Optical Adhesive is spread across the surface of 
a metal AFM specimen disk with either a razor blade or square glass coverslip. The glue 
is cured under a UV lamp for 1.5 minutes. From mildly dry to fully dried filter papers, 
cholesterol crystals are removed with tweezers (note that they tend to stick to the 
tweezers when gripping the crystals) and placed in the middle of the glue on the AFM 
puck. The only force pressing the crystals into the glue is the weight of the crystal itself. 
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With this method, small crystals (ca. 1 mm) do not attach to the tweezers and can only be 
removed from the filter paper with scraping which destroys the crystals. With wet filter 
papers, the crystals stick to the filter paper and do not come off without manual force 
causing crystals to break apart. After crystal placement in the glue, the specimens are 
cured under the UV lamp for another 10 minutes before removal and use for in situ AFM. 
I have prepared growth (supersaturated) and dissolution (undersaturated) solutions 
for in situ AFM by creating solutions with specific concentrations according to the 
methods described for bulk crystallization. After removal from the oven, the 
concentration can be verified using UV-Vis spectrophotometry. The range of 
concentrations useful for imaging will be narrow due to the high solubility and fast 
growth of the crystals. While I have been unable to uncover the growth mechanism of 
cholesterol monohydrate in a mixed aqueous-organic environment of ethanol with 5% 
water at this point in time, I have provided a base platform of knowledge for someone to 
take over this project. 
8.4 Effects of Bile Salts 
Simultaneously while trying to uncover the growth mechanism of cholesterol 
monohydrate, I wanted to visualize the effects of potential inhibitors present in the body 
on the bulk crystallization of cholesterol. Previous studies have found that several bile 
salts, aspirin, osteopontin, and caffeine to inhibit cholesterol crystallization.227-230 There 
are numerous bile salts and I selected five different molecules (Figure 93) to test for 
inhibition: chenodeoxycholic acid, cholic acid, lithocholic acid, deoxycholic acid and 
ursodeoxycholic acid. When performing bulk crystallization, stock solutions of bile salts 
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dissolved in ethanol with 5% water were used to help dissolve cholesterol instead of pure 
solvent.  
 
Figure 93: Five bile salt structures selected to test as potential inhibitors of crystallization. 
Initial studies using 10 mM bile salt and 27.5 mM cholesterol concentration 
reveal effects only for lithocholic acid and ursodeoxycholic acid. Both bile salts show a 
decrease in the number of crystals present on the filter indicating an effect on nucleation. 
However, these bile salts can cause changes in the solubility of cholesterol, which may be 
the cause of the decrease in crystal number. More studies must be performed with these 
bile salts and other potential inhibitors to determine the efficacy and potency along with 
how these potentially act as inhibitors with in situ AFM surface studies. 
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Chapter 9: Summary of the Cholesterol Project and Direction for the Future 
Overall, I have examined the solution properties of cholesterol in a variety of 
alcohol solvents with increasing water content. Solubility increases with higher chain 
length alcohols, reaching a potential maximum at 7-carbon chain length. The alcohol with 
a solubility range comparable to the conditions for gallstones and atherosclerosis is 
ethanol. As the amount of water dissolved in the alcohol increases, the solubility of 
cholesterol decreases. For butanol, we observed an initial increase at low water content 
and then a subsequent decrease at higher water content. If the solubility of cholesterol in 
pure water is compared to that in pure ethanol or a lipid environment, we observe a five 
order of magnitude difference. This result is similar to differences in hematin solubility in 
aqueous and organic media.  
Cholesterol crystals were grown in bulk under a variety of conditions to determine 
which crystal polymorph was formed, the effects on polydispersity of crystals, and 
optimal growth conditions. Water is capable of evaporating from the crystal structure of 
cholesterol, highlighting the importance of selecting a method of drying. The rate of 
cooling is the most influential factor in determining how polydisperse the crystals 
produced will be. Initial perspectives of bile salts as inhibitors of crystallization indicate 
chenodeoxycholic acid and ursodeoxycholic acid affect nucleation and/or the solubility of 
cholesterol.  
Preliminary efforts aimed to uncover the mechanism of crystallization of 
cholesterol monohydrate. The basal surface of cholesterol crystals was examined by 
AFM where steps in the c-direction with heights characteristic of cholesterol 
monohydrate were observed. The process for working with soft cholesterol crystals and 
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mounting them on AFM specimen disks has been determined along with the range of 
cholesterol concentrations leading to surface growth. Overall, I have provided a 
generalized platform for studying the growth of cholesterol crystals.  
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